Hankija vastus - Rahandusministeerium

Failid

Sisu (failidest)

HINDAMISKRITEERIUMID JA HINNATAVAD NÄITAJAD Viitenumber: 294368 Hankija: Aktsiaselts Lääne-Tallinna Keskhaigla (10822269) Hange: Katsutite ja verevõtuvahendite ostmine OSA 1 – VAAKUMKATSUTID JA VEREVÕTU TARVIKUD Pakkumuse maksumust hinnatakse - Ilma maksudeta Kriteeriumi kaalumise meetod - Osakaaludega Elektroonilist oksjoni kasutatakse: ei Jrk Nimetus Kirjeldus Tüüp / Osakaal Kogus Ühik Pakkuja nr hindamismeetod täidetav 1 Osa maksumus vastavalt vorm 2 lahtrile Maksumus - 69 1 HANKE jah H42 (sinine lahter) vähim on parim OSA 2 Täiendav funktsionaalsus Kvaliteet - hankija 31 hinnatav Kokku: 100 Koostatud 04.06.2025 15:33:32 1/6 https://riigihanked.riik.ee/rhr-web/#/procurement/ 8759685/general-info Hindamismetoodika kirjeldus 1. Osa maksumus vastavalt vorm 2 lahtrile H42 (sinine lahter) Madalaima väärtusega pakkumus saab maksimaalse arvu punkte. Teised pakkumused saavad punkte arvutades valemiga: "osakaal" - ("pakkumuse väärtus" - madalaim väärtus") / "suurim väärtus" * "osakaal". 2. Täiendav funktsionaalsus 1. Ohutusnõela (p1.2.1 ja 1.2.2) kaitsemehhanism on nõela (mitte nõelahoidja) külge integreeritud, on kerge, ei liigu ega eelda keerle ümber telje. Ohutusmehhanism, mis on integreeritud nõela külge, ei keerle saab 6 punkti, ülejäänud 0 punkti 2. Ohutusnõela aktiveeritav kaitsemehhanism asetseb eelsätitult nõela ava suunas, vältides vigade ohtu ja ajakulu kaitsemehhanismi keeramisel nõela ava suuna paika sättimiseks. Nõela avaga kohakuti eelseatud kaitsemehhanism saab 6 punkti, ülejäänud 0 punkti 3. Steriilse üksikpakendi avamise järgselt püsib libliknõel kindlalt pakendis, võimaldades avatud tootepakendit asetada tööpinnale ja sealt sujuvat nõelakomplekti väljavõttu. Pakendi avamisel on välistatud nõela pakendist väljalibisemise ja saastumise oht. Toode, mille pakendi kaane avamisel jääb nõelakomplekt pakendisse püsima ja on lauale asetatav edasiseks sujuvaks väljavõtuks ning pakendi lahti rebimisel pole välja libisemise ohtu saab 8 punkti, ülejäänud 0 punkti 4. Libiknõela lukustatav turvakaitse on ühe käega aktiveeritav ilma abivahendeid kasutamata. Kergelt libistamise teel ja ühe käega aktiveeritav kaitsemehhanism saab 5 punkti, ülejäänud 0 punkti. 5. Libliknõelade kasutamine. *Stabiilsus ja konstruktsioon – Nõel ja selle komponendid on hästi kinnitatud, ei logise ega liigu kasutamise ajal. Kui kasutamisel nõel ja selle komponendid logisevad või liiguvad, siis on häire. *Vooliku paindlikkus – voolik on piisavalt elastne (mitte jäik), et võimaldada lihtsat käsitsemist, ei paindu ega murdu blokeerimaks verevoolu. Kui vool on blokeeritud, siis on häire. *Tiivad on ergonoomilised, pole liiga pehmed ega jäigad – lihtne ja kindel haare, püsivad paigas st ei vaju ära ega nihku. Kui tiivad laperdavad ja toode seetõttu pole kindlas asendis, siis on häire. *Tiibade pind on libisemisvastane, kinnastega töötamisel ja käes hoidmisel mugav, ei esine häireid ega libise, mugav käes hoida ka kinnastega töötades. Kui kindaga saab sujuvalt kasutada, siis pole ka häiret. * Turvakaitse aktiveerimisel ei esine takistusi, lukustub kindlalt, ega vaja liigse jõudu kasutamist. Nõude täitmiseks peab turvasüsteem aktiveeruma ühe sujuva liigutusega ega takerdu. Pärast aktiveerimist peab püsima nõel lukustatult fikseeritud asendis, ei võimalda korduvat kasutamist ning ei jää väljapoole nähtavale ega tunda katsudes. Kui kaitsemehhanism ei lukustu, katkeb tööprotsess või on nõel pärast lukustumist taas avatav, loetakse see häireks. *Ühildub nõelahoidajaga - verevool on sujuv, ei blokeeru ega leki üheski süsteemi osas. Kui leket ja blokke ei esine, siis pole ka häiret Kui häireid ei esine- saab 6 punkti. Kui esineb 1-2 häiret – 3 punkti. Kui esineb rohkem kui 2 häiret – 0 punkti. Koostatud 04.06.2025 15:33:32 2/6 https://riigihanked.riik.ee/rhr-web/#/procurement/ 8759685/general-info OSA 2 – OHUTU LIBLIKNÕEL NAISTEKLIINIKULE Pakkumuse maksumust hinnatakse - Ilma maksudeta Kriteeriumi kaalumise meetod - Osakaaludega Elektroonilist oksjoni kasutatakse: ei Jrk Nimetus Kirjeldus Tüüp / Osakaal Kogus Ühik Pakkuja nr hindamismeetod täidetav 1 Osa maksumus vastavalt vorm 2 lahtrile Maksumus - 100 1 HANKE jah H47 (sinine lahter) vähim on parim OSA Kokku: 100 Hindamismetoodika kirjeldus 1. Osa maksumus vastavalt vorm 2 lahtrile H47 (sinine lahter) Madalaima väärtusega pakkumus saab maksimaalse arvu punkte. Teised pakkumused saavad punkte arvutades valemiga: "osakaal" - ("pakkumuse väärtus" - madalaim väärtus") / "suurim väärtus" * "osakaal". OSA 3 – KANNALANTSETID Pakkumuse maksumust hinnatakse - Ilma maksudeta Kriteeriumi kaalumise meetod - Osakaaludega Elektroonilist oksjoni kasutatakse: ei Jrk Nimetus Kirjeldus Tüüp / Osakaal Kogus Ühik Pakkuja nr hindamismeetod täidetav 1 Osa maksumus vastavalt vorm 2 lahtrile Maksumus - 100 1 HANKE jah H52 (sinine lahter) vähim on parim OSA Kokku: 100 Hindamismetoodika kirjeldus 1. Osa maksumus vastavalt vorm 2 lahtrile H52 (sinine lahter) Madalaima väärtusega pakkumus saab maksimaalse arvu punkte. Teised pakkumused saavad punkte arvutades valemiga: "osakaal" - ("pakkumuse väärtus" - madalaim väärtus") / "suurim väärtus" * "osakaal". Koostatud 04.06.2025 15:33:32 3/6 https://riigihanked.riik.ee/rhr-web/#/procurement/ 8759685/general-info OSA 4 – MIKROKATSUTID Pakkumuse maksumust hinnatakse - Ilma maksudeta Kriteeriumi kaalumise meetod - Osakaaludega Elektroonilist oksjoni kasutatakse: ei Jrk Nimetus Kirjeldus Tüüp / Osakaal Kogus Ühik Pakkuja nr hindamismeetod täidetav 1 Osa maksumus vastavalt vorm 2 lahtrile Maksumus - 100 1 HANKE jah H58 (sinine lahter) vähim on parim OSA Kokku: 100 Hindamismetoodika kirjeldus 1. Osa maksumus vastavalt vorm 2 lahtrile H58 (sinine lahter) Madalaima väärtusega pakkumus saab maksimaalse arvu punkte. Teised pakkumused saavad punkte arvutades valemiga: "osakaal" - ("pakkumuse väärtus" - madalaim väärtus") / "suurim väärtus" * "osakaal". OSA 5 – LUER ADAPTER Pakkumuse maksumust hinnatakse - Ilma maksudeta Kriteeriumi kaalumise meetod - Osakaaludega Elektroonilist oksjoni kasutatakse: ei Jrk Nimetus Kirjeldus Tüüp / Osakaal Kogus Ühik Pakkuja nr hindamismeetod täidetav 1 Osa maksumus vastavalt vorm 2 lahtrile Maksumus - 100 1 HANKE jah H64(sinine lahter) vähim on parim OSA Kokku: 100 Hindamismetoodika kirjeldus 1. Osa maksumus vastavalt vorm 2 lahtrile H64(sinine lahter) Madalaima väärtusega pakkumus saab maksimaalse arvu punkte. Teised pakkumused saavad punkte arvutades valemiga: "osakaal" - ("pakkumuse väärtus" - madalaim väärtus") / "suurim väärtus" * "osakaal". Koostatud 04.06.2025 15:33:32 4/6 https://riigihanked.riik.ee/rhr-web/#/procurement/ 8759685/general-info OSA 6 – SÜSTLAD LI-HEPARIINIGA VEREGAASIDE ANALÜÜSIKS Pakkumuse maksumust hinnatakse - Ilma maksudeta Kriteeriumi kaalumise meetod - Osakaaludega Elektroonilist oksjoni kasutatakse: ei Jrk Nimetus Kirjeldus Tüüp / Osakaal Kogus Ühik Pakkuja nr hindamismeetod täidetav 1 Osa maksumus vastavalt vorm 2 lahtrile Maksumus - 90 1 HANKE jah H70 (sinine lahter) vähim on parim OSA 2 Süstla kolvi liikumine. Kvaliteet - hankija 10 hinnatav Kokku: 100 Hindamismetoodika kirjeldus 1. Osa maksumus vastavalt vorm 2 lahtrile H70 (sinine lahter) Madalaima väärtusega pakkumus saab maksimaalse arvu punkte. Teised pakkumused saavad punkte arvutades valemiga: "osakaal" - ("pakkumuse väärtus" - madalaim väärtus") / "suurim väärtus" * "osakaal". 2. Süstla kolvi liikumine. Süstla kolvi liikumine on mõõduka takistusega ega liigu liiga vabalt. Surumisjõu ületamisel ei teki vedeliku kaotuse riski. Optimaalse takistusega kolb saab 10 punkti, ülejäänud 0 punkti OSA 7 – SÜSTLAD LI-HEPARIINIGA VEREGAASIDE ANALÜÜSIKS NAISTEKLIINIKULE Pakkumuse maksumust hinnatakse - Ilma maksudeta Kriteeriumi kaalumise meetod - Osakaaludega Elektroonilist oksjoni kasutatakse: ei Jrk Nimetus Kirjeldus Tüüp / Osakaal Kogus Ühik Pakkuja nr hindamismeetod täidetav 1 Osa maksumus vastavalt vorm 2 lahtrile Maksumus - 90 1 HANKE jah H75 (sinine lahter) vähim on parim OSA 2 Süstla kolvi liikumine Kvaliteet - hankija 10 hinnatav Kokku: 100 Koostatud 04.06.2025 15:33:32 5/6 https://riigihanked.riik.ee/rhr-web/#/procurement/ 8759685/general-info Hindamismetoodika kirjeldus 1. Osa maksumus vastavalt vorm 2 lahtrile H75 (sinine lahter) Madalaima väärtusega pakkumus saab maksimaalse arvu punkte. Teised pakkumused saavad punkte arvutades valemiga: "osakaal" - ("pakkumuse väärtus" - madalaim väärtus") / "suurim väärtus" * "osakaal". 2. Süstla kolvi liikumine Süstla kolvi liikumine on mõõduka takistusega ega liigu liiga vabalt. Surumisjõu ületamisel ei teki vedeliku kaotuse riski. Optimaalse takistusega kolb saab 10 punkti, ülejäänud 0 punkti OSA 8 – TRANSPORTKARP VEREGAASIDE SÜSTLALE JA KATSUTITELE Pakkumuse maksumust hinnatakse - Ilma maksudeta Kriteeriumi kaalumise meetod - Osakaaludega Elektroonilist oksjoni kasutatakse: ei Jrk Nimetus Kirjeldus Tüüp / Osakaal Kogus Ühik Pakkuja nr hindamismeetod täidetav 1 Osa maksumus vastavalt vorm 2 lahtrile Maksumus - 100 1 HANKE jah H80 (sinine lahter) vähim on parim OSA Kokku: 100 Hindamismetoodika kirjeldus 1. Osa maksumus vastavalt vorm 2 lahtrile H80 (sinine lahter) Madalaima väärtusega pakkumus saab maksimaalse arvu punkte. Teised pakkumused saavad punkte arvutades valemiga: "osakaal" - ("pakkumuse väärtus" - madalaim väärtus") / "suurim väärtus" * "osakaal". Koostatud 04.06.2025 15:33:32 6/6 https://riigihanked.riik.ee/rhr-web/#/procurement/ 8759685/general-info PRODUCT CATALOGUE RESULTS OF THE SCIENTIFIC PROCESS 2 RESULTS OF THE SCIENTIFIC PROCESS disera RESULTS OF THE SCIENTIFIC PROCESS INDEX About Us 4 Production 5 VACUSERA Blood Collection Systems 6 VACUSERA Blood Collection System Components and Labeling Symbols 7 VACUSERA Blood Collection Steps 8 VACUSERA Blood Collection Tubes 9 VACUSERA Serum Clot Activator Tubes 10 VACUSERA Serum Gel & Clot Activator and Thrombin Based Serum Gel Tubes 11 VACUSERA K2Edta Tubes 12 VACUSERA K3Edta and K3Edta + Aprotinin Tubes 13 VACUSERA Coagulation Tubes 14 VACUSERA CTAD Tubes 15 VACUSERA Lithium Heparin Tubes 16 VACUSERA Sodium Heparin Tubes 17 VACUSERA No Additive Tubes 18 VACUSERA ACD-A & ACD-B Tubes 19 VACUSERA Trace Element Tubes 20 VACUSERA Crossmatch Tubes 21 VACUSERA Glucose Tubes 22 VACUSERA Blood Collection Needles 23-25 VACUSERA Blood Collection Accessories 26-29 VACUSERA Mini Capillary Blood Collection System 30-31 VACUSERA Sedimentation Systems 32 VACUSERA Urine Collection Systems 33 VACUSERA Blood Collection Systems Order Of Draw 34 3 ABOUT US Disera was founded in 1996 in Izmir, Turkey, initially focusing on the production of laboratory consumables. Today, Disera is one of the leading international companies in the industry, specializing in the production and development of blood collection tubes, blood collection accessories, urine collection systems, and PRP products. Additionally, Disera is active in the laboratory diagnostics sector within its domestic market. For us as a company, patient comfort and the safety of healthcare workers come first. Our core value proposition with our products and services is to improve the overall standard of living and health of communities worldwide. Quality has remained a top priority since the foundation of our company, and all our production sites are committed to the same high standard. All products have the CE mark, and the entire production operation is carried out in accordance with ISO 13485:2016 Quality Management Systems, ISO 14001:2015 Environmental Management Systems and Good Manufacturing Practice (GMP) certificate. We are dedicated to continuous innovation and research. Additionally, our corporate social responsibility initiatives contribute to the community, enhancing our role as a socially responsible organization. OUR MISSION Our mission is to design and manufacture environmentally sustainable, safe and high-quality medical products that comply with all relevant regulations. We are committed to prioritizing customer satisfaction through a customer-oriented approach and engaging with communities and stakeholders to address their needs. By integrating innovative technologies and continuous research into our product design and production processes, we strive to enhance the quality of life and improve community health standards. Additionally, we are committed to the well-being and development of our employees and to adhering to ethical business practices. OUR VISION Our vision is to become one of the leading companies in the healthcare sector, adding significant value to healthcare services worldwide. We embrace innovation and a culture of excellence. By producing high-quality products, we aim to enhance patient quality of life and ensure healthcare professionals can confidently use our products. We prioritize sustainability principles to ensure a safer world for future generations and emphasize the importance of collaborations and partnerships to advance healthcare standards. RESEARCH and DEVELOPMENT Tracking innovations continuously and offering the most suitable products for customers. 4 PRODUCTION Disera Tıbbi Malzeme Lojistik Sanayi ve Ticaret A.Ş having the knowledge and experience on providing quality and technical products in the medical sector, combined with the needs of the healthcare industry innovative product solutions and offers production activities according to the ISO 13485:2016 quality standards. Vacusera Blood Collection Tubes are CE marked according to 98/79/EC In Vitro Diagnostic devices. Vacusera Blood Collection Tubes are produced to the related standards of ISO 6710. Vacusera Blood Collection Needles are CE certified and manufactured according to 93/42/EEC directives. Consistent with a constantly updated technology infrastructure and experienced staff, and also the production quality assurance norms are shaped by different national and international guidelines provide the high quality level of products of Disera. 5 VACUSERA BLOOD COLLECTION SYSTEMS In an increased automation environment in the diagnostic laboratory field and higher standards require a continuous performance of the blood collection systems. Vacusera Blood Collection Tubes, Vacusera Blood Collection Needles and Accessories are designed according to fulfill the requirements of blood collection procedures, patient’s comfort and user’s safety. 6 RESULTS OF THE SCIENTIFIC PROCESS NUMBER VACUSERA BLOOD COLLECTION COMPONENTS LETTER CODE ADDITIVE 1 Vacusera Blood Collection Tube K2E EDTA Dipotassium Salt 2 Safety Cap K3E EDTA Tripotassium Salt 3 Vacusera Safety Holder 9NC Trisodium Citrate 9:1 4 Vacusera Blood Collection Needle 4NC Trisodium Citrate 4:1 5 Vacusera Safety Blood Collection Set with Safety Shield FE Sodium Fluoride / EDTA 6 Vacusera Luer Adapter FX Sodium Fluoride/Potassium Oxalate LH Lithium Heparin NH Sodium Heparin Z None CAT Clot Activator / Clot Activator with Gel CTAD Buffered Citrate 0.109 M ACD-A ACD-A Solution A ACD-B ACD-B Solution B VACUSERA BLOOD COLLECTION SYSTEM LABELLING SYMBOLS Do Not Reuse Sterilized Using Ethylene oxide Use By-Date Sterilized Using Irradiation Batch Code CE Mark Reference Number In Vitro Diagnostic Medical Device Date of Manufacture Consult Instructions for Use Manufacturer Temperature Limit Keep away from sunlight Latex free Do not use if package is damaged Do not Resterilize Keep Dry Caution Non-pyrogenic Non-Sterile Phthalate Free MD Medical Device Single sterile barrier system with protective packaging outside Single Sterile Barrier System 7 BLOOD COLLECTION STEPS 8 RESULTS OF THE SCIENTIFIC PROCESS VACUSERA BLOOD COLLECTION TUBES Vacusera Blood Collection Tubes are made of unbreakable PET tube, butyl rubber stopper and polyethylene cap. We offer medical paper labeled tubes, transparent labeled tubes and also pre- barcoded tubes. All components of Vacusera Blood Collection Systems improve patient’s comfort, help safe and quality blood collection and also reliable test results. PAPER LABELED TUBES TRANSPARENT LABELED TUBES PRE-BARCODED TUBES 9 VACUSERA SERUM CLOT ACTIVATOR TUBES Vacusera Serum Clot Activator Tubes are used for clinical biochemistry and immunology. The inner wall of the Serum Clot Activator Tube is specially coated with clot activator, which activate coagulation process. Reference Draw vol. Size Description Additive Shelf life Label Type Pack/Carton Cap Colour Number (ml) (mm) 234201 VACUSERA 1 ml CAT Serum Clot Activator 1 13 x 75 Clot Activator 18 months Paper 100/1200 234202 VACUSERA 2 ml CAT Serum Clot Activator 2 13 x 75 Clot Activator 18 months Paper 100/1200 234203 VACUSERA 3 ml CAT Serum Clot Activator 3 13 x 75 Clot Activator 18 months Paper 100/1200 234204 VACUSERA 4 ml CAT Serum Clot Activator 4 13 x 75 Clot Activator 18 months Paper 100/1200 235206 VACUSERA 6 ml CAT Serum Clot Activator 6 13 x 100 Clot Activator 18 months Paper 100/1200 236209 VACUSERA 9 ml CAT Serum Clot Activator 9 16 x 100 Clot Activator 18 months Paper 100/1200 236200 VACUSERA 10 ml CAT Serum Clot Activator 10 16 x 100 Clot Activator 18 months Paper 100/1200 434201 VACUSERA 1 ml CAT Serum Clot Activator 1 13 x 75 Clot Activator 18 months Transparent 100/1200 434202 VACUSERA 2 ml CAT Serum Clot Activator 2 13 x 75 Clot Activator 18 months Transparent 100/1200 434203 VACUSERA 3 ml CAT Serum Clot Activator 3 13 x 75 Clot Activator 18 months Transparent 100/1200 434204 VACUSERA 4 ml CAT Serum Clot Activator 4 13 x 75 Clot Activator 18 months Transparent 100/1200 435206 VACUSERA 6 ml CAT Serum Clot Activator 6 13 x 100 Clot Activator 18 months Transparent 100/1200 436209 VACUSERA 9 ml CAT Serum Clot Activator 9 16 x 100 Clot Activator 18 months Transparent 100/1200 436200 VACUSERA 10 ml CAT Serum Clot Activator 10 16 x 100 Clot Activator 18 months Transparent 100/1200 10 RESULTS OF THE SCIENTIFIC PROCESS VACUSERA SERUM GEL AND CLOT ACTIVATOR TUBES Vacusera Serum Separator Tubes contain inert gel; during centrifugation, gel forms a stable barrier between serum and blood cells. Reference Draw vol. Size Cap Description Additive Shelf life Label Type Pack/Carton Number (ml) (mm) Colour 234302 VACUSERA 2 ml CAT Serum GEL and Clot Activator 2 13 x 75 GEL + Clot Activator 18 months Paper 100/1200 234304 VACUSERA 2.5 ml CAT Serum GEL and Clot Activator 2.5 13 x 75 GEL + Clot Activator 18 months Paper 100/1200 234303 VACUSERA 3.5 ml CAT Serum GEL and Clot Activator 3.5 13 x 75 GEL + Clot Activator 18 months Paper 100/1200 235304 VACUSERA 4 ml CAT Serum GEL and Clot Activator 4 13 x 100 GEL + Clot Activator 18 months Paper 100/1200 235305 VACUSERA 5 ml CAT Serum GEL and Clot Activator 5 13 x 100 GEL + Clot Activator 18 months Paper 100/1200 236308 VACUSERA 8 ml CAT Serum GEL and Clot Activator 8 16 x 100 GEL + Clot Activator 18 months Paper 100/1200 236309 VACUSERA 9 ml CAT Serum GEL and Clot Activator 9 16 x 100 GEL + Clot Activator 18 months Paper 100/1200 434302 VACUSERA 2 ml CAT Serum GEL and Clot Activator 2 13 x 75 GEL + Clot Activator 18 months Transparent 100/1200 434304 VACUSERA 2.5 ml CAT Serum GEL and Clot Activator 2.5 13 x 75 GEL + Clot Activator 18 months Transparent 100/1200 434303 VACUSERA 3.5 ml CAT Serum GEL and Clot Activator 3.5 13 x 75 GEL + Clot Activator 18 months Transparent 100/1200 435304 VACUSERA 4 ml CAT Serum GEL and Clot Activator 4 13 x 100 GEL + Clot Activator 18 months Transparent 100/1200 435305 VACUSERA 5 ml CAT Serum GEL and Clot Activator 5 13 x 100 GEL + Clot Activator 18 months Transparent 100/1200 436308 VACUSERA 8 ml CAT Serum GEL and Clot Activator 8 16 x 100 GEL + Clot Activator 18 months Transparent 100/1200 436309 VACUSERA 9 ml CAT Serum GEL and Clot Activator 9 16 x 100 GEL + Clot Activator 18 months Transparent 100/1200 VACUSERA THROMBIN BASED SERUM GEL TUBES Vacusera thrombin based serum tubes provide rapid blood clotting by means of thrombin based clot activator and allow rapid serum separation together with the inert gel in the tubes. Reference Draw vol. Size Cap Description Additive Shelf life Label Type Pack/Carton Number (ml) (mm) Colour GEL + Clot Activator 235315 VACUSERA 5 ml CAT Serum GEL and Thrombin 5 13 x 100 + Thrombin 12 months Paper 100/1200 GEL + Clot Activator 435315 VACUSERA 5 ml CAT Serum GEL and Thrombin 5 13 x 100 + Thrombin 12 months Transparent 100/1200 11 VACUSERA K2EDTA TUBES Vacusera K2EDTA Tubes are for examination of whole blood in haematology. K2EDTA and GEL is mainly used for molecular diagnostics. Reference Draw vol. Size Description Additive Shelf life Label Type Pack/Carton Cap Colour Number (ml) (mm) 234601 VACUSERA 1 ml K2E/K2EDTA 1 13 x 75 K2E K2EDTA 18 months Paper 100/1200 234602 VACUSERA 2 ml K2E/K2EDTA 2 13 x 75 K2E K2EDTA 18 months Paper 100/1200 234603 VACUSERA 3 ml K2E/K2EDTA 3 13 x 75 K2E K2EDTA 18 months Paper 100/1200 234604 VACUSERA 4 ml K2E/K2EDTA 4 13 x 75 K2E K2EDTA 18 months Paper 100/1200 234605 VACUSERA 4.5 ml K2E/K2EDTA 4.5 13 x 75 K2E K2EDTA 18 months Paper 100/1200 235606 VACUSERA 6 ml K2E/K2EDTA 6 13 x 100 K2E K2EDTA 18 months Paper 100/1200 236609 VACUSERA 9 ml K2E/K2EDTA 9 16 x 100 K2E K2EDTA 18 months Paper 100/1200 434601 VACUSERA 1 ml K2E/K2EDTA 1 13 x 75 K2E K2EDTA 18 months Transparent 100/1200 434602 VACUSERA 2 ml K2E/K2EDTA 2 13 x 75 K2E K2EDTA 18 months Transparent 100/1200 434603 VACUSERA 3 ml K2E/K2EDTA 3 13 x 75 K2E K2EDTA 18 months Transparent 100/1200 434604 VACUSERA 4 ml K2E/K2EDTA 4 13 x 75 K2E K2EDTA 18 months Transparent 100/1200 434605 VACUSERA 4.5 ml K2E/K2EDTA 4.5 13 x 75 K2E K2EDTA 18 months Transparent 100/1200 435606 VACUSERA 6 ml K2E/K2EDTA 6 13 x 100 K2E K2EDTA 18 months Transparent 100/1200 436609 VACUSERA 9 ml K2E/K2EDTA 9 16 x 100 K2E K2EDTA 18 months Transparent 100/1200 234623 VACUSERA 3 ml K2E/K2EDTA + GEL 3 13 x 75 GEL + K2E K2EDTA 18 months Paper 100/1200 235625 VACUSERA 5 ml K2E/K2EDTA + GEL 5 13 x 100 GEL + K2E K2EDTA 18 months Paper 100/1200 236628 VACUSERA 8 ml K2E/K2EDTA + GEL 8 16 x 100 GEL + K2E K2EDTA 18 months Paper 100/1200 434623 VACUSERA 3 ml K2E/K2EDTA + GEL 3 13 x 75 GEL + K2E K2EDTA 18 months Transparent 100/1200 435625 VACUSERA 5 ml K2E/K2EDTA + GEL 5 13 x 100 GEL + K2E K2EDTA 18 months Transparent 100/1200 436628 VACUSERA 8 ml K2E/K2EDTA + GEL 8 16 x 100 GEL + K2E K2EDTA 18 months Transparent 100/1200 12 RESULTS OF THE SCIENTIFIC PROCESS VACUSERA K3EDTA TUBES Vacusera K3EDTA Tubes are for examination of whole blood in haematology. Reference Draw vol. Size Description Additive Shelf life Label Type Pack/Carton Cap Colour Number (ml) (mm) 234611 VACUSERA 1 ml K3E/K3EDTA 1 13 x 75 K3E K3EDTA 18 months Paper 100/1200 234612 VACUSERA 2 ml K3E/K3EDTA 2 13 x 75 K3E K3EDTA 18 months Paper 100/1200 234613 VACUSERA 3 ml K3E/K3EDTA 3 13 x 75 K3E K3EDTA 18 months Paper 100/1200 234614 VACUSERA 4 ml K3E/K3EDTA 4 13 x 75 K3E K3EDTA 18 months Paper 100/1200 234615 VACUSERA 4.5 ml K3E/K3EDTA 4.5 13 x 75 K3E K3EDTA 18 months Paper 100/1200 235616 VACUSERA 6 ml K3E/K3EDTA 6 13 x 100 K3E K3EDTA 18 months Paper 100/1200 236619 VACUSERA 9 ml K3E/K3EDTA 9 16 x 100 K3E K3EDTA 18 months Paper 100/1200 434611 VACUSERA 1 ml K3E/K3EDTA 1 13 x 75 K3E K3EDTA 18 months Transparent 100/1200 434612 VACUSERA 2 ml K3E/K3EDTA 2 13 x 75 K3E K3EDTA 18 months Transparent 100/1200 434613 VACUSERA 3 ml K3E/K3EDTA 3 13 x 75 K3E K3EDTA 18 months Transparent 100/1200 434614 VACUSERA 4 ml K3E/K3EDTA 4 13 x 75 K3E K3EDTA 18 months Transparent 100/1200 434615 VACUSERA 4.5 ml K3E/K3EDTA 4.5 13 x 75 K3E K3EDTA 18 months Transparent 100/1200 435616 VACUSERA 6 ml K3E/K3EDTA 6 13 x 100 K3E K3EDTA 18 months Transparent 100/1200 436619 VACUSERA 9 ml K3E/K3EDTA 9 16 x 100 K3E K3EDTA 18 months Transparent 100/1200 VACUSERA K3E/K3EDTA + APROTININ TUBES Vacusera K3EDTA + Aprotinin tubes allow us to work ACTH tests in room temperature. Reference Draw vol. Size Description Additive Shelf life Label Type Pack/Carton Cap Colour Number (ml) (mm) 234654 VACUSERA 4 ml K3E/K3EDTA + Aprotinin 4 13 x 75 K3E/K3EDTA + Aprotinin 12 months Paper 100/1200 235656 VACUSERA 6 ml K3E/K3EDTA + Aprotinin 6 13 x 100 K3E/K3EDTA + Aprotinin 12 months Paper 100/1200 434654 VACUSERA 4 ml K3E/K3EDTA + Aprotinin 4 13 x 75 K3E/K3EDTA + Aprotinin 12 months Transparent 100/1200 435656 VACUSERA 6 ml K3E/K3EDTA + Aprotinin 6 13 x 100 K3E/K3EDTA + Aprotinin 12 months Transparent 100/1200 13 VACUSERA COAGULATION TUBES Vacusera Coagulation Tubes are used for blood coagulation tests. Coagulation Tubes have a buffered sodium citrate solution of 0.109 mol/l (3.2%) or 0.129 mol/l (3.8 %). Double Tube (*DT) technology provides an excellent condition for coagulation tests. VACUSERA 9NC COAGULATION SODIUM CITRATE 3.2% Reference Draw vol. Size Pack Cap Description Additive Shelf life Label Type Number (ml) (mm) /Carton Colour 234501 VACUSERA 1 ml Coagulation 3.2% Sodium Citrate - DT 1 13 x 75 9NC Sodium Citrate 3.2%(0.109M) 9 months Paper 100/1200 234502 VACUSERA 1.8 ml Coagulation 3.2% Sodium Citrate - DT 1.8 13 x 75 9NC Sodium Citrate 3.2%(0.109M) 9 months Paper 100/1200 234503 VACUSERA 2.7 ml Coagulation 3.2% Sodium Citrate - DT 2.7 13 x 75 9NC Sodium Citrate 3.2%(0.109M) 9 months Paper 100/1200 234504 VACUSERA 3.6 ml Coagulation 3.2% Sodium Citrate 3.6 13 x 75 9NC Sodium Citrate 3.2%(0.109M) 4 months Paper 100/1200 234505 VACUSERA 4.5 ml Coagulation 3.2% Sodium Citrate 4.5 13 x 75 9NC Sodium Citrate 3.2%(0.109M) 4 months Paper 100/1200 235505 VACUSERA 5 ml Coagulation 3.2% Sodium Citrate 5 13 x 100 9NC Sodium Citrate 3.2%(0.109M) 4 months Paper 100/1200 434501 VACUSERA 1 ml Coagulation 3.2% Sodium Citrate - DT 1 13 x 75 9NC Sodium Citrate 3.2%(0.109M) 9 months Transparent 100/1200 434502 VACUSERA 1.8 ml Coagulation 3.2% Sodium Citrate - DT 1.8 13 x 75 9NC Sodium Citrate 3.2%(0.109M) 9 months Transparent 100/1200 434503 VACUSERA 2.7 ml Coagulation 3.2% Sodium Citrate - DT 2.7 13 x 75 9NC Sodium Citrate 3.2%(0.109M) 9 months Transparent 100/1200 434504 VACUSERA 3.6 ml Coagulation 3.2% Sodium Citrate 3.6 13 x 75 9NC Sodium Citrate 3.2%(0.109M) 4 months Transparent 100/1200 434505 VACUSERA 4.5 ml Coagulation 3.2% Sodium Citrate 4.5 13 x 75 9NC Sodium Citrate 3.2%(0.109M) 4 months Transparent 100/1200 435505 VACUSERA 5 ml Coagulation 3.2% Sodium Citrate 5 13 x 100 9NC Sodium Citrate 3.2%(0.109M) 4 months Transparent 100/1200 VACUSERA 9NC COAGULATION SODIUM CITRATE 3.8% Reference Draw vol. Size Pack Cap Description Additive Shelf life Label Type Number (ml) (mm) /Carton Colour 234511 VACUSERA 1 ml Coagulation 3.8% Sodium Citrate - DT 1 13 x 75 9NC Sodium Citrate %3.8(0.129M) 9 months Paper 100/1200 234512 VACUSERA 1.8 ml Coagulation 3.8% Sodium Citrate - DT 1.8 13 x 75 9NC Sodium Citrate %3.8(0.129M) 9 months Paper 100/1200 234513 VACUSERA 2.7 ml Coagulation 3.8% Sodium Citrate - DT 2.7 13 x 75 9NC Sodium Citrate %3.8(0.129M) 9 months Paper 100/1200 234514 VACUSERA 3.6 ml Coagulation 3.8% Sodium Citrate 3.6 13 x 75 9NC Sodium Citrate %3.8(0.129M) 4 months Paper 100/1200 234515 VACUSERA 4.5 ml Coagulation 3.8% Sodium Citrate 4.5 13 x 75 9NC Sodium Citrate %3.8(0.129M) 4 months Paper 100/1200 235515 VACUSERA 5 ml Coagulation 3.8% Sodium Citrate 5 13 x 100 9NC Sodium Citrate %3.8(0.129M) 4 months Paper 100/1200 434511 VACUSERA 1 ml Coagulation 3.8% Sodium Citrate - DT 1 13 x 75 9NC Sodium Citrate %3.8(0.129M) 9 months Transparent 100/1200 434512 VACUSERA 1.8 ml Coagulation 3.8% Sodium Citrate - DT 1.8 13 x 75 9NC Sodium Citrate %3.8(0.129M) 9 months Transparent 100/1200 434513 VACUSERA 2.7 ml Coagulation 3.8% Sodium Citrate - DT 2.7 13 x 75 9NC Sodium Citrate %3.8(0.129M) 9 months Transparent 100/1200 434514 VACUSERA 3.6 ml Coagulation 3.8% Sodium Citrate 3.6 13 x 75 9NC Sodium Citrate %3.8(0.129M) 4 months Transparent 100/1200 434515 VACUSERA 4.5 ml Coagulation 3.8% Sodium Citrate 4.5 13 x 75 9NC Sodium Citrate %3.8(0.129M) 4 months Transparent 100/1200 435515 VACUSERA 5 ml Coagulation 3.8% Sodium Citrate 5 13 x 100 9NC Sodium Citrate %3.8(0.129M) 4 months Transparent 100/1200 *DT: Double Tube 14 RESULTS OF THE SCIENTIFIC PROCESS VACUSERA CTAD TUBES Vacusera CTAD Tubes are used for coagulation tests. Buffered Citrate Solution consists Theophylline Adenosine, Dipyridamole. CTAD Tubes are used for reliable test results by preventing activation of in vitro thrombocyte. Reference Draw vol. Size Pack Description Additive Shelf life Label Type Cap Colour Number (ml) (mm) /Carton 234522 VACUSERA 1.8 ml CTAD - DT 1.8 13 x 75 Buffered Sodium Citrate 3.2% (0.109) 9 months Paper 100/1200 234523 VACUSERA 2.7 ml CTAD - DT 2.7 13 x 75 Buffered Sodium Citrate 3.2% (0.109) 9 months Paper 100/1200 234524 VACUSERA 3.6 ml CTAD 3.6 13 x 75 Buffered Sodium Citrate 3.2% (0.109) 4 months Paper 100/1200 234525 VACUSERA 4.5 ml CTAD 4.5 13 x 75 Buffered Sodium Citrate 3.2% (0.109) 4 months Paper 100/1200 434522 VACUSERA 1.8 ml CTAD - DT 1.8 13 x 75 Buffered Sodium Citrate 3.2% (0.109) 9 months Transparent 100/1200 434523 VACUSERA 2.7 ml CTAD - DT 2.7 13 x 75 Buffered Sodium Citrate 3.2% (0.109) 9 months Transparent 100/1200 434524 VACUSERA 3.6 ml CTAD 3.6 13 x 75 Buffered Sodium Citrate 3.2% (0.109) 4 months Transparent 100/1200 434525 VACUSERA 4.5 ml CTAD 4.5 13 x 75 Buffered Sodium Citrate 3.2% (0.109) 4 months Transparent 100/1200 DT: Double Tube 15 VACUSERA HEPARIN TUBES Vacusera Heparin Tubes are coated with Lithium Heparin or Sodium Heparin to inhibit clotting. Sodium Heparin or Lithium Heparin Tubes are used for plasma determinations in clinical chemistry. Heparin Tubes are also available with gel separator. VACUSERA LH LITHIUM HEPARIN TUBES Reference Draw vol. Size Pack Description Additive Shelf life Label Type Cap Colour Number (ml) (mm) /Carton 234402 VACUSERA 2 ml LH/Lithium Heparin 2 13 x 75 LH/Lithium Heparin 18 months Paper 100/1200 234404 VACUSERA 4 ml LH/Lithium Heparin 4 13 x 75 LH/Lithium Heparin 18 months Paper 100/1200 235406 VACUSERA 6 ml LH/Lithium Heparin 6 13 x 100 LH/Lithium Heparin 18 months Paper 100/1200 236409 VACUSERA 9 ml LH/Lithium Heparin 9 16 x 100 LH/Lithium Heparin 18 months Paper 100/1200 434402 VACUSERA 2 ml LH/Lithium Heparin 2 13 x 75 LH/Lithium Heparin 18 months Transparent 100/1200 434404 VACUSERA 4 ml LH/Lithium Heparin 4 13 x 75 LH/Lithium Heparin 18 months Transparent 100/1200 435406 VACUSERA 6 ml LH/Lithium Heparin 6 13 x 100 LH/Lithium Heparin 18 months Transparent 100/1200 436409 VACUSERA 9 ml LH/Lithium Heparin 9 16 x 100 LH/Lithium Heparin 18 months Transparent 100/1200 234413 VACUSERA 3 ml LH/Lithium Heparin + GEL 3 13 x 75 GEL + LH/Lithium Heparin 18 months Paper 100/1200 235415 VACUSERA 5 ml LH/Lithium Heparin + GEL 5 13 x 100 GEL + LH/Lithium Heparin 18 months Paper 100/1200 236418 VACUSERA 8 ml LH/Lithium Heparin + GEL 8 16 x 100 GEL + LH/Lithium Heparin 18 months Paper 100/1200 434413 VACUSERA 3 ml LH/Lithium Heparin + GEL 3 13 x 75 GEL + LH/Lithium Heparin 18 months Transparent 100/1200 435415 VACUSERA 5 ml LH/Lithium Heparin + GEL 5 13 x 100 GEL + LH/Lithium Heparin 18 months Transparent 100/1200 436418 VACUSERA 8 ml LH/Lithium Heparin + GEL 8 16 x 100 GEL + LH/Lithium Heparin 18 months Transparent 100/1200 16 RESULTS OF THE SCIENTIFIC PROCESS VACUSERA NH SODIUM HEPARIN TUBES Vacusera Sodium Heparin Tubes are used for plasma determinations in clinical chemistry. VACUSERA NH SODIUM HEPARIN Reference Draw vol. Size Pack Description Additive Shelf life Label Type Cap Colour Number (ml) (mm) /Carton 234424 VACUSERA 4 ml NH/Sodium Heparin 4 13 x 75 NH/Sodium Heparin 18 months Paper 100/1200 235426 VACUSERA 6 ml NH/Sodium Heparin 6 13 x 100 NH/Sodium Heparin 18 months Paper 100/1200 236429 VACUSERA 9 ml NH/Sodium Heparin 9 16 x 100 NH/Sodium Heparin 18 months Paper 100/1200 434424 VACUSERA 4 ml NH/Sodium Heparin 4 13 x 75 NH/Sodium Heparin 18 months Transparent 100/1200 435426 VACUSERA 6 ml NH/Sodium Heparin 6 13 x 100 NH/Sodium Heparin 18 months Transparent 100/1200 436429 VACUSERA 9 ml NH/Sodium Heparin 9 16 x 100 NH/Sodium Heparin 18 months Transparent 100/1200 234433 VACUSERA 3 ml NH/Sodium Heparin + GEL 3 13 x 75 GEL + Sodium Heparin 18 months Paper 100/1200 235435 VACUSERA 5 ml NH/Sodium Heparin + GEL 5 13 x 100 GEL + Sodium Heparin 18 months Paper 100/1200 236438 VACUSERA 8 ml NH/Sodium Heparin + GEL 8 16 x 100 GEL + Sodium Heparin 18 months Paper 100/1200 434433 VACUSERA 3 ml NH/Sodium Heparin + GEL 3 13 x 75 GEL + Sodium Heparin 18 months Transparent 100/1200 435435 VACUSERA 5 ml NH/Sodium Heparin + GEL 5 13 x 100 GEL + Sodium Heparin 18 months Transparent 100/1200 436438 VACUSERA 8 ml NH/Sodium Heparin + GEL 8 16 x 100 GEL + Sodium Heparin 18 months Transparent 100/1200 17 VACUSERA NO ADDITIVE TUBES VACUSERA no additive tubes are used in determinations for clinical chemistry and hormones, microbiological serology, and immunology. VACUSERA no additive tubes do not contain any additive but are evacuated and the interior is sterile. They can be used as discard tubes or for the collection of blood. Reference Draw vol. Size Description Additive Shelf life Label Type Pack/Carton Cap Colour Number (ml) (mm) 234102 VACUSERA 2 ml Z No Additive 2 13 x 75 No Additive 18 months Paper 100/1200 234104 VACUSERA 4 ml Z No Additive 4 13 x 75 No Additive 18 months Paper 100/1200 235106 VACUSERA 6 ml Z No Additive 6 13 x 100 No Additive 18 months Paper 100/1200 236109 VACUSERA 9 ml Z No Additive 9 16 x 100 No Additive 18 months Paper 100/1200 236100 VACUSERA 10 ml Z No Additive 10 16 x 100 No Additive 18 months Paper 100/1200 434102 VACUSERA 2 ml Z No Additive 2 13 x 75 No Additive 18 months Transparent 100/1200 434104 VACUSERA 4 ml Z No Additive 4 13 x 75 No Additive 18 months Transparent 100/1200 435106 VACUSERA 6 ml Z No Additive 6 13 x 100 No Additive 18 months Transparent 100/1200 436109 VACUSERA 9 ml Z No Additive 9 16 x 100 No Additive 18 months Transparent 100/1200 436100 VACUSERA 10 ml Z No Additive 10 16 x 100 No Additive 18 months Transparent 100/1200 18 RESULTS OF THE SCIENTIFIC PROCESS VACUSERA ACD-A & ACD-B TUBES Vacusera Blood Grouping Tubes contain 2 formulations as ACD-A & ACD-B solutions and are used in Blood Grouping. Reference Draw vol. Size Description Additive Shelf life Label Type Pack/Carton Cap Colour Number (ml) (mm) 235726 VACUSERA 6 ML ACD-A 6 13 x 100 ACD-A 12 months Paper 100/1200 236729 VACUSERA 9 ML ACD-A 9 16 x 100 ACD-A 12 months Paper 100/1200 235736 VACUSERA 6 ML ACD-B 6 13 x 100 ACD-B 12 months Paper 100/1200 236739 VACUSERA 9 ML ACD-B 9 16 x 100 ACD-B 12 months Paper 100/1200 435726 VACUSERA 6 ML ACD-A 6 13 x 100 ACD-A 12 months Transparent 100/1200 436729 VACUSERA 9 ML ACD-A 9 16 x 100 ACD-A 12 months Transparent 100/1200 435736 VACUSERA 6 ML ACD-B 6 13 x 100 ACD-B 12 months Transparent 100/1200 436739 VACUSERA 9 ML ACD-B 9 16 x 100 ACD-B 12 months Transparent 100/1200 19 VACUSERA TRACE ELEMENT TUBES Vacusera Trace Element tubes are used for determining the elements of Iron, Zinc, Copper, Mercury and Lead. Tubes consist Clot Activator, K2EDTA or Sodium Heparin. Reference Draw vol. Size Cap Description Additive Shelf life Label Type Pack/Carton Number (ml) (mm) Colour 235006 VACUSERA 6 ml Trace Element CAT Serum Clot Activator 6 13 x 100 Clot Activator 18 months Paper 100/1200 235016 VACUSERA 6 ml Trace Element NH/Sodium Heparin 6 13 x 100 Sodium Heparin 18 months Paper 100/1200 235026 VACUSERA 6 ml Trace Element K2E/K2EDTA 6 13 x 100 K2EDTA 18 months Paper 100/1200 435006 VACUSERA 6 ml Trace Element CAT Serum Clot Activator 6 13 x 100 Clot Activator 18 months Transparent 100/1200 435016 VACUSERA 6 ml Trace Element NH/Sodium Heparin 6 13 x 100 Sodium Heparin 18 months Transparent 100/1200 435026 VACUSERA 6 ml Trace Element K2E/K2EDTA 6 13 x 100 K2EDTA 18 months Transparent 100/1200 20 RESULTS OF THE SCIENTIFIC PROCESS VACUSERA CROSSMATCH TUBES Vacusera Crossmatch tubes contain silica particles as clot activator and K2EDTA / K3EDTA as anticoagulant. Reference Draw vol. Size Cap Description Additive Shelf life Label Type Pack/Carton Number (ml) (mm) Colour 235216 VACUSERA 6 ml Crossmatch CAT Serum Clot Activator 6 13 x 100 Clot Activator 18 months Paper 100/1200 236219 VACUSERA 9 ml Crossmatch CAT Serum Clot Activator 9 16 x 100 Clot Activator 18 months Paper 100/1200 234634 VACUSERA 4 ml Crossmatch K2E/K2EDTA 4 13 x 75 K2EDTA 18 months Paper 100/1200 235636 VACUSERA 6 ml Crossmatch K2E/K2EDTA 6 13 x 100 K2EDTA 18 months Paper 100/1200 234644 VACUSERA 4 ml Crossmatch K3E/K3EDTA 4 13 x 75 K3EDTA 18 months Paper 100/1200 235646 VACUSERA 6 ml Crossmatch K3E/K3EDTA 6 13 x 100 K3EDTA 18 months Paper 100/1200 435216 VACUSERA 6 ml Crossmatch CAT Serum Clot Activator 6 13 x 100 Clot Activator 18 months Transparent 100/1200 436219 VACUSERA 9 ml Crossmatch CAT Serum Clot Activator 9 16 x 100 Clot Activator 18 months Transparent 100/1200 434634 VACUSERA 4 ml Crossmatch K2E/K2EDTA 4 13 x 75 K2EDTA 18 months Transparent 100/1200 435636 VACUSERA 6 ml Crossmatch K2E/K2EDTA 6 13 x 100 K2EDTA 18 months Transparent 100/1200 434644 VACUSERA 4 ml Crossmatch K3E/K3EDTA 4 13 x 75 K3EDTA 18 months Transparent 100/1200 435646 VACUSERA 6 ml Crossmatch K3E/K3EDTA 6 13 x 100 K3EDTA 18 months Transparent 100/1200 21 VACUSERA GLUCOSE TUBES Vacusera Glucose Tubes contain Sodium Fluoride and K3EDTA, Sodium Fluoride and Potassium Oxalate and also Sodium Fluoride + Na2 Edta. Glucose tubes are used for glucose determinations like blood sugar, sugar tolerance, etanol and alcohol ratio in blood. VACUSERA FE/SODIUM FLUORIDE + K3EDTA Reference Draw vol. Size Description Additive Shelf life Label Type Pack/Carton Cap Colour Number (ml) (mm) 234702 VACUSERA 2 ml FE/Sodium Fluoride + K3EDTA 2 13 x 75 FE/Sodium Fluoride + K3EDTA 18 months Paper 100/1200 234704 VACUSERA 4 ml FE/Sodium Fluoride + K3EDTA 4 13 x 75 FE/Sodium Fluoride + K3EDTA 18 months Paper 100/1200 434702 VACUSERA 2 ml FE/Sodium Fluoride + K3EDTA 2 13 x 75 FE/Sodium Fluoride + K3EDTA 18 months Transparent 100/1200 434704 VACUSERA 4 ml FE/Sodium Fluoride + K3EDTA 4 13 x 75 FE/Sodium Fluoride + K3EDTA 18 months Transparent 100/1200 VACUSERA FX/SODIUM FLUORIDE + POTASSIUM OXALATE Reference Draw vol. Size Label Pack/ Cap Description Additive Shelf life Number (ml) (mm) Type Carton Colour FX/Sodium Fluoride + Potassium 234712 VACUSERA 2 ml FX/Sodium Fluoride + Potassium Oxalate 2 13 x 75 Oxalate 18 months Paper 100/1200 FX/Sodium Fluoride + Potassium 234714 VACUSERA 4 ml FX/Sodium Fluoride + Potassium Oxalate 4 13 x 75 Oxalate 18 months Paper 100/1200 FX/Sodium Fluoride + Potassium 434712 VACUSERA 2 ml FX/Sodium Fluoride + Potassium Oxalate 2 13 x 75 Oxalate 18 months Transparent 100/1200 FX/Sodium Fluoride + Potassium 434714 VACUSERA 4 ml FX/Sodium Fluoride + Potassium Oxalate 4 13 x 75 Oxalate 18 months Transparent 100/1200 VACUSERA FE/SODIUM FLUORIDE+NA2 EDTA Reference Draw vol. Size Pack/ Description Additive Shelf life Label Type Cap Colour Number (ml) (mm) Carton 234722 VACUSERA 2 ml FE/Sodium Fluoride + NA2EDTA 2 13 x 75 FE/Sodium Fluoride + NA2EDTA 18 months Paper 100/1200 234724 VACUSERA 4 ml FE/Sodium Fluoride + NA2EDTA 4 13 x 75 FE/Sodium Fluoride + NA2EDTA 18 months Paper 100/1200 235725 VACUSERA 5 ml FE/Sodium Fluoride + NA2EDTA 5 13 x 100 FE/Sodium Fluoride + NA2EDTA 18 months Paper 100/1200 434722 VACUSERA 2 ml FE/Sodium Fluoride + NA2EDTA 2 13 x 75 FE/Sodium Fluoride + NA2EDTA 18 months Transparent 100/1200 434724 VACUSERA 4 ml FE/Sodium Fluoride + NA2EDTA 4 13 x 75 FE/Sodium Fluoride + NA2EDTA 18 months Transparent 100/1200 435725 VACUSERA 5 ml FE/Sodium Fluoride + NA2EDTA 5 13 x 100 FE/Sodium Fluoride + NA2EDTA 18 months Transparent 100/1200 22 RESULTS OF THE SCIENTIFIC PROCESS 23 VACUSERA BLOOD COLLECTION NEEDLES Vacusera Blood Collection Needles are used in blood collection, single-used and sterile. The needles are coated with silicone, a low friction and ensuring very soft vein entry. The colour of needle hub identifies needle gauge. Vacusera Blood Collection Needles are also available with integrated safety cap and window (Vision). 24 RESULTS OF THE SCIENTIFIC PROCESS VACUSERA BLOOD COLLECTION NEEDLES Reference Description Size Pack/Carton Colour Number 250018K Blood Collection Needle 18 G 18 G x 1 1/2” (1.2x38mm) 100/5000 250018KW Blood Collection Needle 18 G 18 G x 1 1/2” (1.2x38mm) 100/5000 250020K Blood Collection Needle 20 G 20 G x 1 1/2” (0.9x38mm) 100/5000 250020KW Blood Collection Needle 20 G 20 G x 1 1/2” (0.9x38mm) 100/5000 250021K Blood Collection Needle 21 G 21 G x 1 1/2” (0.8x38mm) 100/5000 250021KW Blood Collection Needle 21 G 21 G x 1 1/2” (0.8x38mm) 100/5000 250022K Blood Collection Needle 22 G 22 G x 1 1/2” (0.7x38mm) 100/5000 250022KW Blood Collection Needle 22 G 22 G x 1 1/2” (0.7x38mm) 100/5000 250023K Blood Collection Needle 23 G 23 G x 1 1/2” (0,6x38mm) 100/5000 250023KW Blood Collection Needle 23 G 23 G x 1 1/2” (0,6x38mm) 100/5000 253018K Blood Collection Needle 18 G 18 G x 1” (1,2x25mm) 100/5000 253018KW Blood Collection Needle 18 G 18 G x 1” (1,2x25mm) 100/5000 253020K Blood Collection Needle 20 G 20 G x 1” (0,9x25mm) 100/5000 253020KW Blood Collection Needle 20 G 20 G x 1” (0,9x25mm) 100/5000 253021K Blood Collection Needle 21 G 21 G x 1” (0.8x25mm) 100/5000 253021KW Blood Collection Needle 21 G 21 G x 1” (0.8x25mm) 100/5000 253022K Blood Collection Needle 22 G 22 G x 1” (0.7x25mm) 100/5000 253022KW Blood Collection Needle 22 G 22 G x 1” (0.7x25mm) 100/5000 253023K Blood Collection Needle 23 G 23 G x 1” (0,6x25mm) 100/5000 253023KW Blood Collection Needle 23 G 23 G x 1” (0,6x25mm) 100/5000 255020K Blood Collection Needle 20 G - VISION 20 G x 1 1/2” (0.9x38mm) 100/5000 255021K Blood Collection Needle 21 G - VISION 21 G x 1 1/2” (0.8x38mm) 100/5000 255022K Blood Collection Needle 22 G - VISION 22 G x 1 1/2” (0.7x38mm) 100/5000 255023K Blood Collection Needle 23 G - VISION 23 G x 1” (0,6x25mm) 100/5000 261021K Needle Vision + Safety Holder 21 G 21 G x 1 1/2” (0.8x38mm) 24/192 261022K Needle Vision + Safety Holder 22 G 22 G x 1 1/2” (0.7x38mm) 24/192 251021K Integrated Safety Needle 21 G 21 G x 1 1/4” (0.8x32mm) 48/2400 251021KW Integrated Safety Needle 21 G 21 G x 1 1/4” (0.8x32mm) 48/2400 251022K Integrated Safety Needle 22 G 22 G x 1 1/4” (0.7x32mm) 48/2400 251022KW Integrated Safety Needle 22 G 22 G x 1 1/4” (0.7x32mm) 48/2400 252020 Luer Adapter 20 G 20 G 100/5000 25 VACUSERA ACCESSORIES Vacusera Accessories provide necessary products for blood collection. BLOOD COLLECTION SETS WITH SAFETY SHIELD Vacusera Safety Blood Collection Sets are used for blood collection from difficult veins like children and elder people. Safety mechanism protects healthcare workers from needle stick injury. Reference Description Size Pack/Carton Colour Number 24121190K Blood Collection Set with Safety Shield 21 G 3/4'' x 7'' 0.8 x 19mm x 180mm 100/2000 24121300K Blood Collection Set with Safety Shield 21 G 3/4'' x 12'' 0.8 x 19mm x 305mm 100/2000 24122190K Blood Collection Set with Safety Shield 22 G 3/4'' x 7'' 0.7 x 19mm x 180mm 100/2000 24122300K Blood Collection Set with Safety Shield 22 G 3/4'' x 12'' 0.7 x 19mm x 305mm 100/2000 24123190K Blood Collection Set with Safety Shield 23 G 3/4'' x 7'' 0.6 x 19mm x 180mm 100/2000 24123300K Blood Collection Set with Safety Shield 23 G 3/4'' x 12'' 0.6 x 19mm x 305mm 100/2000 24125190K Blood Collection Set with Safety Shield 25 G 3/4'' x 7'' 0.5 x 19mm x 180mm 100/2000 24125300K Blood Collection Set with Safety Shield 25 G 3/4'' x 12'' 0.5 x 19mm x 305mm 100/2000 24121190G Blood Collection Set with Safety Shield 21 G 3/4’’ x 7.5’’ 0.8 x 20mm x 190mm 100/900 24121300G Blood Collection Set with Safety Shield 21 G 3/4'' x 12'' 0.8 x 20mm x 300mm 100/900 24123190G Blood Collection Set with Safety Shield 23 G 3/4'' x 7.5’’ 0.6 x 20mm x 190mm 100/900 24123300G Blood Collection Set with Safety Shield 23 G 3/4'' x 12'' 0.6 x 20mm x 300mm 100/900 24125190G Blood Collection Set with Safety Shield 25 G 3/4'' x 7.5’’ 0.5 x 20mm x 190mm 100/900 24125300G Blood Collection Set with Safety Shield 25 G 3/4'' x 12'' 0.5 x 20mm x 300mm 100/900 24321190K Vacusera Safe Plus® Safety Blood Collection Set 21G 3/4” x 7’’ 0.8 x 19mm x 178mm 100/2000 24321300K Vacusera Safe Plus® Safety Blood Collection Set 21 G 3/4" x 12" 0.8 x 19mm x 305mm 100/2000 24323190K Vacusera Safe Plus® Safety Blood Collection Set 23 G 3/4" x 7" 0.6 x 19mm x 178mm 100/2000 24323300K Vacusera Safe Plus® Safety Blood Collection Set 23 G 3/4" x 12" 0.6 x 19mm x 305mm 100/2000 24325190K Vacusera Safe Plus® Safety Blood Collection Set 25 G 3/4" x 7" 0.5 x 19mm x 178mm 100/2000 24325300K Vacusera Safe Plus® Safety Blood Collection Set 25 G 3/4" x 12" 0.5 x 19mm x 305mm 100/2000 26 RESULTS OF THE SCIENTIFIC PROCESS BLOOD COLLECTION SETS WITH SAFETY SHIELD + HOLDER Vacusera Safety Blood Collection Sets are also available with Pre-Attached holder. Reference Description Size Pack/Carton Colour Number 24221190K Blood Collection Set with Safety Shield + Holder 21 G 3/4'' x 7'' 0.8 x 19mm x 180mm 25/500 24221300K Blood Collection Set with Safety Shield + Holder 21 G 3/4'' x 12'' 0.8 x 19mm x 305mm 25/500 24222190K Blood Collection Set with Safety Shield + Holder 22 G 3/4'' x 7'' 0.7 x 19mm x 180mm 25/500 24222300K Blood Collection Set with Safety Shield + Holder 22 G 3/4'' x 12'' 0.7 x 19mm x 305mm 25/500 24223190K Blood Collection Set with Safety Shield + Holder 23 G 3/4'' x 7'' 0.6 x 19mm x 180mm 25/500 24223300K Blood Collection Set with Safety Shield + Holder 23 G 3/4'' x 12'' 0.6 x 19mm x 305mm 25/500 24225190K Blood Collection Set with Safety Shield + Holder 25 G 3/4'' x 7'' 0.5 x 19mm x 180mm 25/500 24225300K Blood Collection Set with Safety Shield + Holder 25 G 3/4'' x 12'' 0.5 x 19mm x 305mm 25/500 24221190G Blood Collection Set with Safety Shield + Holder 21 G 3/4'' x 7,5'' 0.8 x 20mm x 190mm 50/400 24221300G Blood Collection Set with Safety Shield + Holder 21 G 3/4'' x 12'' 0.8 x 20mm x 300mm 50/400 24223190G Blood Collection Set with Safety Shield + Holder 23 G 3/4'' x 7,5'' 0.6 x 20mm x 190mm 50/400 24223300G Blood Collection Set with Safety Shield + Holder 23 G 3/4'' x 12'' 0.6 x 20mm x 300mm 50/400 24225190G Blood Collection Set with Safety Shield + Holder 25 G 3/4'' x 7,5'' 0.5 x 20mm x 190mm 50/400 24225300G Blood Collection Set with Safety Shield + Holder 25 G 3/4'' x 12'' 0.5 x 20mm x 300mm 50/400 24421190K Vacusera Safe Plus® Safety Blood Collection Set + Holder 21 G 3/4" x 7" 0.8 x 19mm x 178mm 25/500 24421300K Vacusera Safe Plus® Safety Blood Collection Set + Holder 21 G 3/4" x 12" 0.8 x 19mm x 305mm 25/500 24423190K Vacusera Safe Plus® Safety Blood Collection Set + Holder 23 G 3/4" x 7" 0.6 x 19mm x 178mm 25/500 24423300K Vacusera Safe Plus® Safety Blood Collection Set + Holder 23 G 3/4" x 12" 0.6 x 19mm x 305mm 25/500 24425190K Vacusera Safe Plus® Safety Blood Collection Set + Holder 25 G 3/4" x 7" 0.5 x 19mm x 178mm 25/500 24425300K Vacusera Safe Plus® Safety Blood Collection Set + Holder 25 G 3/4" x 12" 0.5 x 19mm x 305mm 25/500 27 28 RESULTS OF THE SCIENTIFIC PROCESS BLOOD COLLECTION NEEDLES + SAFETY HOLDER Reference Description Pack/Carton Number 260018K Blood Collection Needle + Safety Holder 18 G x 1 1/2” (1.2x38mm) 25/500 260020K Blood Collection Needle + Safety Holder 20 G x 1 1/2” (0.9x38mm) 25/500 260021K Blood Collection Needle + Safety Holder 21 G x 1 1/2” (0.8x38mm) 25/500 260022K Blood Collection Needle + Safety Holder 22 G x 1 1/2” (0.7x38mm) 25/500 260023K Blood Collection Needle + Safety Holder 23 G x 1 1/2” (0.6x38mm) 25/500 HOLDERS Vacusera Holders are compatible with Vacusera Blood Collection Needles and Vacusera Blood Collection Tubes. It provides safety and easy use for healthcare workers. Reference Description Pack/Carton Number 260001 Blood Collection Needle Holder 200/1000 260002 Safety Holder 200/800 260003 Automatic Holder 200/800 260004 Blood Collection Holder with Female Luer Lock 200/800 260005 Blood Collection Holder with Male Luer Lock 200/800 260006K Luer Adapter + Blood Collection Needle Holder 200/800 VACUSERA TOURNIQUET Vacusera Tourniquet is used for tying the vein during blood collection. It is safe and easy to use. Reference Description Pack/Carton Number 259001 Automatic Tourniquet 1 pc / 500 pcs 259001-1 Automatic Tourniquet for children - Green 1 pc / 500 pcs 259001-2 Automatic Tourniquet for children - Pink 1 pc / 500 pcs 259050 Disposable Tourniquet 50 pcs / box VACUSERA SHARPS DISPOSAL CONTAINER For disposal of used sharp objects like cannulas, scalpels, needles, holders, syringes etc. Available in 2.1 lt. and 7.5 lt. Reference Description Quantity/Box Number 101175 Sharps Disposal Container 7.5 lt. 40 pcs / box 101121 Sharps Disposal Container 2.1 lt. 100 pcs / box 29 VACUSERA MINI CAPILLARY BLOOD COLLECTION SYSTEM Vacusera Mini Capillary Blood Collection System provides all the necessary products for pediatric need. VACUSERA MINI CAPILLARY BLOOD COLLECTION TUBES Vacusera Mini Capillary Blood Collection Tubes are designed with safety cap for collecting high quality capillary blood sample. VACUSERA MINI SERUM TUBES Reference Draw Pack Cap Description Additive Number vol. (ml) /Carton Colour 238202 VACUSERA MINI 0.2 ml CAT Serum Clot Activator 0.2 Clot Activator 50/1000 238205 VACUSERA MINI 0.5 ml CAT Serum Clot Activator 0.5 Clot Activator 50/1000 GEL + Clot 238302 VACUSERA MINI 0.2 ml CAT Serum GEL + Clot Activator 0.2 50/1000 Activator GEL + Clot 238305 VACUSERA MINI 0.5 ml CAT Serum GEL + Clot Activator 0.5 50/1000 Activator VACUSERA MINI EDTA TUBES Reference Draw Pack Cap Description Additive Number vol. (ml) /Carton Colour 238602 VACUSERA MINI 0.2 ml K2E/K2EDTA 0.2 K2E K2EDTA 50/1000 238605 VACUSERA MINI 0.5 ml K2E/K2EDTA 0.5 K2E K2EDTA 50/1000 238612 VACUSERA MINI 0.2 ml K3E/K3EDTA 0.2 K3E K3EDTA 50/1000 238615 VACUSERA MINI 0.5 ml K3E/K3EDTA 0.5 K3E K3EDTA 50/1000 238625 VACUSERA MINI 0.5 ml K2E/K2EDTA (13x75mm) 0.5 K2E K2EDTA 100/1000 VACUSERA MINI HEPARIN TUBES Reference Draw Pack Cap Description vol. (ml) Additive Number /Carton Colour 238402 VACUSERA MINI 0.2 ml LH/Lithium Heparin 0.2 LH/Lithium Heparin 50/1000 238405 VACUSERA MINI 0.5 ml LH/Lithium Heparin 0.5 LH/Lithium Heparin 50/1000 238412 VACUSERA MINI 0.2 ml LH/Lithium Heparin + GEL 0.2 LH/Lithium Heparin+GEL 50/1000 238415 VACUSERA MINI 0.5 ml LH/Lithium Heparin + GEL 0.5 LH/Lithium Heparin + GEL 50/1000 238422 VACUSERA MINI 0.2 ml NH/Sodium Heparin 0.2 NH/Sodium Heparin 50/1000 238425 VACUSERA MINI 0.5 ml NH/Sodium Heparin 0.5 NH/Sodium Heparin 50/1000 30 RESULTS OF THE SCIENTIFIC PROCESS VACUSERA MINI GLUCOSE TUBES Reference Draw vol. Pack Cap Description Additive Number (ml) /Carton Colour 238701 VACUSERA MINI 0.2 ml FE/K2EDTA 0.2 FE/Sodium Fluoride + K2EDTA 50/1000 238705 VACUSERA MINI 0.5 ml FE/K2EDTA 0.5 FE/ Sodium Fluoride + K2EDTA 50/1000 VACUSERA MINI COAGULATION TUBES Reference Draw Pack Cap Description Additive Number vol. (ml) /Carton Colour 238505 VACUSERA MINI 0.5 ml Coagulation Sodium Citrate 3.2% 0.5 Sodium Citrate 3.2% 50/1000 VACUSERA LANCETS Vacusera Lancets provide consistent puncture depth for easy safe sample collection. Reference Draw vol. Pack / Cap Description Number (mm) Carton Colour 2393018N VACUSERA Pressure activated safety blood lancet 30G/1.8mm 30G/1.8mm 100/1000 2393015N VACUSERA Pressure activated safety blood lancet 30G/1.5mm 30G/1.5mm 100/1000 2392818N VACUSERA Pressure activated safety blood lancet 28G/1.8mm 28G/1.8mm 100/1000 2392815N VACUSERA Pressure activated safety blood lancet 28G/1.5mm 28G/1.5mm 100/1000 2392618N VACUSERA Pressure activated safety blood lancet 26G/1.8mm 26G/1.8mm 100/1000 2392518N VACUSERA Pressure activated safety blood lancet 25G/1.8mm 25G/1.8mm 100/1000 2392322N VACUSERA Pressure activated safety blood lancet 23G/2.2mm 23G/2.2mm 100/1000 2392318N VACUSERA Pressure activated safety blood lancet 23G/1.8mm 23G/1.8mm 100/1000 2392128N VACUSERA Pressure activated safety blood lancet 21G/2.8mm 21G/2.8mm 100/1000 2392122N VACUSERA Pressure activated safety blood lancet 21G/2.2mm 21G/2.2mm 100/1000 2392118N VACUSERA Pressure activated safety blood lancet 21G/1.8mm 21G/1.8mm 100/1000 2392118BN VACUSERA Pressure activated safety blood lancet - Blade 21G/1.8mm 21G/1.8mm 100/1000 2391818N VACUSERA Pressure activated safety blood lancet 18G/1.8mm 18G/1.8mm 100/1000 2391818BN VACUSERA Pressure activated safety blood lancet - Blade 18G/1.8mm 18G/1.8mm 100/1000 31 VACUSERA SEDIMENTATION SYSTEMS Vacusera Sedimentation Tubes are consisting 3.2% sodium citrate for ESR test. VACUSERA CLOSED SEDIMENTATION SYSTEM Reference Draw Size Pack/ Cap Description Additive Shelf life Label Type Number vol. (ml) (mm) Carton Colour 233903 VACUSERA 1.28 ml Glass ESR Tube 1.28 8 x 120 4NC Sodium Citrate 3.2% 24 months Paper 100/1000 233902 VACUSERA 1.6 ml Glass ESR Tube 1.6 9 x 120 4NC Sodium Citrate 3.2% 24 months Paper 100/1000 290020 VACUSERA 20 ESR analyzer 1/1 290100 VACUSERA 100 ESR analyzer 1/1 233901 VACUSERA 1.28 ml & 1.6 ml ESR Rack 1/10 VACUSERA OPEN SEDIMENTATION SYSTEM Reference Draw Size Pack/ Cap Description Additive Shelf life Label Type Number vol. (ml) (mm) Carton Colour 234902 VACUSERA 2 ml ESR Tube 2 13 x 75 4NC Sodium Citrate 3.2% 12 months Paper 100/1200 234900 VACUSERA Disposable ESR Pipette 60 months 200/2000 234901 VACUSERA ESR RACK without graduation for 234902 & 434902 (Vacusera Open Sedimentation System) 1/25 32 RESULTS OF THE SCIENTIFIC PROCESS VACUSERA URINE COLLECTION SYSTEMS Vacusera Urine Collection Systems provide easy and comfortable use with urine tubes and integrated urine beaker for healthcare workers. Reference Draw vol. Size Cap Description Additive Shelf life Label Type Pack/Carton Number (ml) (mm) Colour 234814 VACUSERA 4 ml Urine Tube - Boric Acid 4 13 x 75 Boric Acid 18 months Paper 100/1200 235806 VACUSERA 6 ml Urine Tube - No Additive 6 13 x 100 No Additive 18 months Paper 100/1200 236808 VACUSERA 8 ml Urine Tube - No Additive 8 16 x 100 No Additive 18 months Paper 100/1200 236800 VACUSERA 10 ml Urine Tube - No Additive 10 16 x 100 No Additive 18 months Paper 100/1200 235816 VACUSERA 6 ml Urine Tube - Boric Acid 6 13 x 100 Boric Acid 18 months Paper 100/1200 236810 VACUSERA 10 ml Urine Tube - Boric Acid 10 16 x 100 Boric Acid 18 months Paper 100/1200 236828 VACUSERA 8 ml Urine Tube - Chlorhexidine 8 16 x 100 Chlorhexidine 18 months Paper 100/1200 236820 VACUSERA 10 ml Urine Tube - Chlorhexidine 10 16 x 100 Chlorhexidine 18 months Paper 100/1200 434814 VACUSERA 4 ml Urine Tube - Boric Acid 4 13 x 75 Boric Acid 18 months Transparent 100/1200 435806 VACUSERA 6 ml Urine Tube - No Additive 6 13 x 100 No Additive 18 months Transparent 100/1200 436808 VACUSERA 8 ml Urine Tube - No Additive 8 16 x 100 No Additive 18 months Transparent 100/1200 436800 VACUSERA 10 ml Urine Tube - No Additive 10 16 x 100 No Additive 18 months Transparent 100/1200 435816 VACUSERA 6 ml Urine Tube - Boric Acid 6 13 x 100 Boric Acid 18 months Transparent 100/1200 436810 VACUSERA 10 ml Urine Tube - Boric Acid 10 16 x 100 Boric Acid 18 months Transparent 100/1200 436828 VACUSERA 8 ml Urine Tube - Chlorhexidine 8 16 x 100 Chlorhexidine 18 months Transparent 100/1200 436820 VACUSERA 10 ml Urine Tube - Chlorhexidine 10 16 x 100 Chlorhexidine 18 months Transparent 100/1200 103023 VACUSERA Urine Beaker with Integrated Holder 100 ml (Nonsterile) 100 No Additive 36 months 300 103026 VACUSERA Urine Beaker with Integrated Holder 100 ml in a single bag (Sterile) 100 No Additive 36 months 300 103033 VACUSERA 24 Hourly Integrated Urine Collection Cap 3L. 3000 60 months 14 236839 VACUSERA 9 ml Urine Tube – No Additive – Conical Bottom 9 16 x 100 No Additive 18 months Paper 100/1200 236848 VACUSERA 8 ml Urine Tube – Boric Acid – Conical Bottom 8 16 x 100 Boric Acid 18 months Paper 100/1200 236859 VACUSERA 9 ml Urine Tube – Chlorhexidine – Conical Bottom 9 16 x 100 Chlorhexidine 18 months Paper 100/1200 33 VACUSERA BLOOD COLLECTION SYSTEMS ORDER OF DRAW DRAW VOL COLOR CODE TUBE TYPE DESCRIPTION MIXING CENTRIFUGE SPEED & TIME 1ml / 1.8 ml COAGULATION SODIUM CITRATE 3-4 2000-2500 g (RCF)10 -15 MIN 2.7 ml / 3.6 ml / 4.5 ml TEST SEDIMENTATION 3-4 1.28 ml / 1.6 ml / 2 ml ESR TEST 6 ml / 9 ml BLOOD ACD 3-4 GROUPING 1 ml / 2 ml / 3 ml / 4 ml 6 ml / 9 ml / 10 ml CLOT ACTIVATOR SERUM TEST 5-6 1300 g (RCF) 10 MIN 2 ml / 2.5 ml / 3.5 ml 5 ml / 8 ml CLOT ACTIVATOR + GEL SERUM TEST 5-6 2000-3000 g (RCF) 10 -15* MIN CLOT ACTIVATOR 2000-3000 g (RCF) 10 -15* MIN 5 ml SERUM TEST 5-6 THROMBIN + GEL 4000 g (RCF) 5 MIN LITHIUM HEPARIN 2 m / 4 ml / 6 ml / 9 ml PLASMA TEST 8-10 1300 g (RCF) 10 MIN SODIUM HEPARIN LITHIUM HEPARIN + GEL 3 ml / 5 ml / 8 ml PLASMA TEST 8-10 1300-2000 g (RCF) 10 MIN SODIUM HEPARIN + GEL 1 ml / 2 ml / 3 ml / 4 ml HAEMATOLOGY EDTA 8-10 4.5 ml / 6 ml / 9 ml TEST MOLECULAR 3 ml / 5 ml / 8 ml EDTA + GEL 8-10 1100-1500 g (RCF) 10 MIN DIAGNOSTIC CROSS MATCH CROSS MATCH CLOT ACTIVATOR TEST 5-6 1300 g (RCF) 10 MIN 6 ml / 9 ml CROSS MATCH CROSS MATCH 4 ml / 6 ml TEST 8-10 K2EDTA / K3EDTA FE / SODIUM FLUORIDE 2 ml / 4 ml + EDTA GLUCOSE TEST 8-10 1300 g (RCF) 10 MIN FX/ SODIUM FLUORIDE 2 ml / 4 ml GLUCOSE TEST 8-10 1300 g (RCF) 10 MIN + POTASSIUM OXALATE 6 ml TRACE ELEMENT TRACE ELEMENT 1300 g (RCF) 10 MIN 5-6 CLOT ACTIVATOR TEST TRACE ELEMENT TRACE ELEMENT 8-10 1300 g (RCF) 10 MIN 6 ml NH/SODIUM HEPARIN TEST TRACE ELEMENT TRACE ELEMENT 6 ml 8-10 K2EDTA TEST Insufficient blood volume and mixing properly can effect the test results and may cause re-collection of blood. * With ﬁxed-angle rotors 15 minutes - With swing-out rotors 10 minutes 34 RESULTS OF THE SCIENTIFIC PROCESS 35 www.pixelstudio.com.tr - Designed by Kenan Demiroğlu - © 700902-V9 -0.KT.STS.001,00,21.03.2025_EN RESULTS OF THE SCIENTIFIC PROCESS Disera Tıbbi Malzeme Lojistik Sanayi ve Ticaret A.Ş. Head Office: 5758 Sok. No:4 H/11 P.K. 35110 / Karabağlar - İZMİR / TÜRKİYE Factory 1: İbni Melek O.S.B Mah. Tosbi Yol 5 Sk. No: 46 Tire - İZMİR / TÜRKİYE Factory 2: İbni Melek O.S.B Mah. Tosbi Yol 1. Sk. No: 1/1, Tire - İZMİR / TÜRKİYE Factory 3: İbni Melek O.S.B Mah. Tosbi Yol 5. Sk. No:32/A Tire - İZMİR / TÜRKİYE Phone: +90 (232) 264 66 68 Fax: +90 (232) 264 84 00 www.disera.com.tr - www.vacusera.com Bouya S, et al. Global Prevalence and Device Related Causes of Needle Stick Injuries among Health Care Workers: A Systematic Review and Meta-Analysis. Annals of Global Health. 2020; 86(1): 35, 1–8. DOI: https://doi.org/10.5334/aogh.2698 REVIEW Global Prevalence and Device Related Causes of Needle Stick Injuries among Health Care Workers: A Systematic Review and Meta-Analysis Salehoddin Bouya*, Abbas Balouchi†, Hosien Rafiemanesh‡, Mehrbanoo Amirshahi§, Majid Dastres‖, Mahdieh Poodineh Moghadam¶, Niaz Behnamfar**, Mahmood Shyeback††, Mahin Badakhsh¶, Jasem Allahyari‡‡, Adhra Al Mawali§§, Abbas Ebadi‖‖,¶¶, Asiyeh Dezhkam*** and Karen A. Daley††† Background: Healthcare workers (HCWs) suffer more than 2 million occupational needle-stick injuries (NSIs) annually. Goal: To determine the global prevalence and causes of NSIs among HCWs. Methods: In this systematic review and meta-analysis, three databases (PubMed, Web of science, and Scopus) were searched for reports from January 1, 2000 to December 31, 2018. The random effects model was used to determine the prevalence of NSIs among HCWs. Hoy et al.’s instrument was employed to evaluate the quality of the included studies. Findings: A total of 87 studies performed on 50,916 HCWs in 31 countries worldwide were included in the study. The one-year global pooled prevalence of NSIs among HCWs was 44.5% (95% CI: 35.7, 53.2). Highest prevalence of NSIs occurred in the South East Asia region at 58.2% (95%, CI: 36.7, 79.8). By job category, prevalence of NSIs was highest among dentists at 59.1% (95% CI: 38.8, 79.4), Hypodermic needles were the most common cause of NSIs at 55.1% (95% CI: 41.4, 68.9). Conclusion: The current high prevalence of NSIs among HCWs suggests need to improve occupational health services and needle-stick education programs globally. Introduction Safety and Health at Work (EU-OSHA) reports, there are Currently, needlestick injuries (NSIs) are one of the most more than 385,000 and 1,000,000 NSIs cases annually important occupational hazards among healthcare work- among hospital HCWs in the United States and Europe, ers (HCWs) globally. According to WHO, more than two respectively [3, 4]. WHO statistics also show that NSIs million occupational exposures to sharp injuries occur cause 16,000, 66,000, and 1,000 cases of HCV, HBV, and among 35 million HCWs annually [1]. HIV per year among HCWs, respectively [5]. The preva- NSIs increase the risk of over 20 types of infectious lence of various infectious diseases due to NSIs among diseases among HCWs, including hepatitis B, hepatitis HCWs is not a single and integrated phenomenon, rather C, and HIV [2]. According to the Centers for Disease is affected by several factors, such as vaccination rates Control and Prevention (CDC) and European Agency for among HCWs, access to appropriate worker protection * Internal Medicine and Nephrology, Clinical Immunology †† Bushehr University of Medical Sciences, Bushehr, IR Research Center, Ali-Ebne Abitaleb Hospital, Zahedan ‡‡ Zahedan University of medical sciences, Zahedan, IR University of Medical Sciences, Zahedan, IR † Student Research Committee, Nursing and Midwifery School, §§ Centre of Studies and Research, Oman Ministry of Health, Iran University of Medical Sciences, Tehran, IR Muscat, OM ‡ Student Research Committee, Department of Epidemiology, ‖‖ Behavioral Sciences Research Center, Life style institute, School of Public Health and Safety, Shahid Beheshti University Baqiyatallah University of Medical Sciences, Tehran, IR of Medical Sciences, Tehran, IR § Department of Midwifery, Zabol University of Medical ¶¶ Nursing Faculty, Baqiyatallah University of Medical Sciences, Sciences, Zabol, IR Tehran, IR ‖ Nursing and Midwifery school, Zahedan University of Medical *** Department of Pediaterics, Iranshahr University of Medical Sciences, Zahedan, IR Sciences, Iranshahr, IR ¶ Department of Nursing, Faculty of Nursing and Midwifery, ††† American Nurses Association, Massachusetts, US Zabol University of Medical Sciences, Zabol, IR ** Department of Nursing, Faculty of nursing and midwifery, Corresponding author: Mehrbanoo Amirshahi, MSc Tehran medical sciences, Islamic Azad university, Tehran, IR ([email protected]) Art. 35, page 2 of 8 Bouya et al: Global Prevalence and Device Related equipment and post exposure prophylaxis (PEP), and nursing and medical students, and other members of compliance with precautionary infection control stand- the health team. Exclusion criteria included studies ards [6]. Additionally, the prevalence of NSIs is not the published in non-English language before 2000, stud- same among all HCWs, and NSIs occur more frequently ies that reviewed the prevalence of needle stick among among nurses, surgeons, and emergency personnel [7, patients and other populations. As well as the studies 8]. that reported the prevalence of needle stick at other time Each NSI case imposes a direct and indirect cost of 175 periods, including last three months, or six months, or to 350 USD to the health care system [9]. NSI prevention lifetime. Reviews, letters to the editor, high risk stud- is very important among HCWs. The first step in planning ies, short reports as well non-full text studies were also to prevent NSIs is to determine its precise prevalence excluded. rate, which is difficult due to a range of factors includ- ing predominantly voluntary reporting, lack of common Search strategy denominators, lack of national surveillance systems, and Three databases (PubMed, Web of science, and Scopus) suspected frequency of injury underreporting. Despite the were searched from January 1, 2000 to December 31, importance of this issue, and in spite of individual studies, 2018. The PubMed search strategy was adopted to search there are currently no accurate statistics on the global in other databases. The search strategy was developed with prevalence of NSIs among HCWs, especially in develop- the help of an experienced librarian in the field of sys- ing and less developed countries. Existing statistics are tematic review studies in the health field. A combination mainly published at the national level and are relevant of boolean operators (AND, OR, and NOT), Medical Sub- to a limited number of developed countries. A national ject Headings (MeSH), truncation “*”, Emtree and related study conducted in the United States in 2017 referred to keywords were used to search the articles. Keywords of NSI as the main cause of percutaneous injuries in more the search included: Prevalence OR “Needlestick Injury” than 71% of reported cases among HCWs [10]. Moreover, OR “sharp injuries” OR “health care workers” OR “health the results of annual surveys, even in developed countries professionals” (Supplementary Table 2). such as the United States, have shown that despite the dif- ferent strategies implemented, there is still an increasing Selection of studies, data extraction and quality incidence of NSIs among HCWs [11]. assessment Determining the global prevalence and causes of NSIs Two researchers independently conducted search, screen- may enable NSI rate reduction, creation of safer work ing, selection, and extraction of study data according environments and safety cultures, reduced turnover rate, to the study protocol. Disagreements were resolved via reduced costs, and ultimately, provision of higher quality consensus method. After removing duplicates, the titles services among HCWs [12–14]. Previous reviews have of the remaining articles were checked based on the pur- examined the prevalence of NSIs only in a specific ward pose of the study and inclusion criteria. Then the abstract or only at the national level (Pakistan and Iran), or have of the articles was examined and non-relevant items investigated needlestick-related prevention and cost bur- were excluded. Finally, the full-texts of included articles den dimensions [9, 15–17]. To the best of our knowledge, was reviewed. Then the required data was extracted in there has been no specific study on the global prevalence Microsoft Excel based on the study extraction form. The of NSIs so far. The aim of this study was to determine the extracted data included: First Author, Year of publication, global prevalence and device related causes of NSIs among Country, Region (based on WHO categories in six group HCWs. [African, Americans], EMRO [Eastern Mediterranean], European, South-East Asia, Western Pacific), Socio-demo- Methods graphic Index (SDI) status based on World Bank catego- Registration and Eligibility Criteria ries in four groups (high SDI, high middle SDI, low middle The study protocol has been registered in International SDI, and low SDI), study period, sampling method, target Prospective Register of Systematic Reviews, known as population, type of study setting, participants, gender, PROSPERO (CRD42019131562). This study was con- prevalence of NSI/SI, causes of NSI/SI, and Risk of bias. ducted using Cochrane guideline and reported using The Hoy tool, specially designed for observational studies, the Preferred Reporting Items for Systematic Reviews was used to assess the quality of the studies included [19]. and Meta-Analyses (PRISMA) statement (Supplementary This 10-item tool evaluated the quality of studies in two Table 1) [18]. dimensions including external validity (items 1–4 assess Observational studies (cross-sectional) published in target population, sampling method and nonresponse peer-reviewed journals from January 1, 2000 to December bias minimal) and internal validity (items 5–9 assess data 31, 2018, conducted on healthcare workers, carried out collection method, case definition, study instrument, on at least 25 people, were included in the study. Studies mode of data collection and item 10 assesses bias related that aimed to determine the prevalence and causes of to the analysis). NSIs in at least one healthcare group over the past year were included [1]. The latest search on databases was per- Data synthesis formed on January 1, 2019. HCWs in this study include We have reported all the retrieved data on global preva- all employees who work in the health care system and lence of NSIs in different groups, based on job catego- are exposed to NSIs. HCWs included physicians, nurses, ries of HCWs, WHO regions, country, and SDI. A random Bouya et al: Global Prevalence and Device Related Art. 35, page 3 of 8 effects meta-analysis was conducted to determine pooled Study characteristics one-year prevalence estimates (with 95% confidence A total of 87 studies performed on 50,916 HCWs in 31 intervals [Cis]) of NSIs among HCWs. Also, sub-groups countries from 2000 to 2018 were entered into the meta- and meta-regression analyses were conducted to deter- analysis. Most studies were conducted in the Eastern mine heterogeneity. The heterogeneity of the preliminary Mediterranean region (EMRO) (n = 28) and western pacific studies was evaluated using I2 tests, which determine the regions (n = 20). Most studies were conducted in coun- percentage of variation between studies due to heteroge- tries with middle to high SIDs (N = 65). The studies lasted neity, rather than by chance. In addition, meta-regression anywhere between one day and 19 months. Most studies analyses were conducted for describing the linear relation- used census sampling (N = 34). Among HCWs, nurses were ship between (both continuous and categorical) study- studied in most studies (n = 50). Moreover, most studies level covariates and the prevalence of NSIs. Meta-analysis were multicenter research studies (n = 53). Of the 50,916 was performed using STATA 14 (StataCorp, Texas, USA) participants, most were nurses (n = 28371). All of the stud- statistical software. ies included had low risk of bias (Supplementary Table 3). Results Global prevalence of NSIs among HCWs Study selection Prevalence of needle stick injuries (NSIs) (occurrence of A total of 3335 studies were retrieved from searches in at least 1 NSI within previous 12 months) was assessed in three databases. Out of 2872 non-duplicated studies 87 studies conducted in 31 countries. Prevalence of NSIs in the title and summary screening process, 2655 stud- in all HCWs was reported to be between 3.5 and 100%. ies were excluded due to unrelated titles and abstracts. Based on the results of the random effects method, the Out of 217 studies, 87 met eligibility criteria. Out of 130 global prevalence of NSIs in all the 50,916 HCWs studied excluded studies, 18 studies were reviews, four studies was 44.5% (95% CI: 35.7, 53.2; I2 = 99.9%). Sub-group were letters to the editor, five studies were brief reports, analysis based on WHO regions showed that the pooled 11 studies have no full text, 39 studies were published in prevalence of NSIs in nurses was the lowest in Americans non-English language, and 23 studies did not meet the and the Western Pacific regions, and was the highest in minimum overall quality requirements for inclusion in the EMRO. The pooled prevalence in the EMRO was 1.9 the study. Also, 30 articles were excluded from the study times higher than that in America (52.0 vs. 26.7) and since they reported the prevalence rate as life-time, 3, or 6 this difference was significant. The pooled prevalence months (Figure 1). in South-East Asia (58.2%) and the EMRO (53.5%) were Figure 1: Study flow diagram. Art. 35, page 4 of 8 Bouya et al: Global Prevalence and Device Related higher than that in the Western Pacific (30.9%), Amer- reported NSI distribution by sex. Of the 2428 male and ica (39.4%), and the African (41.7%) regions (Figure 2). the 6009 female HCWs, 890 and 2357 NSIs were respec- Among the 31 countries, the pooled prevalence in Singa- tively reported globally. The pooled prevalence was pore (based-on two studies), New Zealand (based-on one slightly higher in women than in men (44.1% vs 39.8%), study), and Australia (based-on three studies) was lower although this difference was not significant. Statistical than 15% and higher than 70% in Sri-Lanka (based- difference was also observed between the WHO regions on one study) (Figure 3). Of the 31 studies, 18 studies (Supplementary Figure 1). Figure 2: Global Prevalence of Needlestick injuries among health care workers based on WHO region. Figure 3: Global Prevalence of Needle stick injuries among health care workers based on Countries. Bouya et al: Global Prevalence and Device Related Art. 35, page 5 of 8 Sub-group analysis based-on two time period, before between 3.5% and 94.6%, and the pooled prevalence was and after 2010, did not show a significant difference 40.8% (95% CI: 23.1, 58.6; I2 = 99.6%). in the prevalence of NSIs in the world, although in America region pooled prevalence in after 2010 was sig- Dentists nificantly 3.4 time more than before 2010. So, trend of NSIs were reported in 889 of 1368 dentists, the preva- NSIs prevalence only was significant for America region lence from 4 studies was between 27.5% and 69.2%, and (P-value = 0.016) (Supplementary Table 4). the pooled prevalence was 59.1% (95% CI: 38.8, 79.4; I2 = 98.2%). NSIs were reported in 266 out of 367 dentist Global prevalence of NSIs among HCWs based on type students and the prevalence from 2 studies was between of job 71.7% and 73.7%. NSIs were reported in 221 out of 3822 Nurses HIV cases, the prevalence from 4 studies was between In this review, NSI data were extracted from eight groups 1.0% and 58.6%, and the pooled prevalence was 11.5% of HCWs. NSIs were reported in 9739 of 28,197 nurses, (95% CI: 5.6, 17.3; I2 = 98.0%). the prevalence from 50 studies was between 2.6% and 100%, and the pooled prevalence was 42.8% (95% CI: Global prevalence of NSIs By socio-economic 35.5, 50.1; I2 = 99.7%). Sub-group analysis based-on WHO development (SDI) regions showed that the pooled prevalence of NSIs in Of all studies, 26 studies conducted in high socio-economic nurses was the lowest in the Western Pacific and America development (SDI), 39 study in high middle SDI, 13 and regions, and was the highest in South-East Asia, followed 9 studies in lower middle and low SDI, respectively. Sub- by the EMRO. The difference between the American and group analysis based-on socio-economic development EMRO was significant and the pooled prevalence for the (SDI) showed pooled prevalence of NSIs for all HCWs in EMRO was 1.9 times higher than that in America (52.0 vs. high SDI was lower than other SDI groups and this dif- 26.7) (Supplementary Figure 2). ference was significant with lower middle SDI (37.6% vs. 61.0%). Also, in nurses and physician, the prevalence in Physicians high SDI were 2.2 and 1.9 time significantly lower than NSIs were reported in 1578 of 3602 physicians, the lower middle SDI (Table 1). prevalence from 22 studies was between 10.5% and 86.2%, and the pooled prevalence was 46.4% (95% CI: Meta-regression finding 34.1, 58.8; I2 = 98.8%). Sub-group analysis based-on The results of univariate meta-regression analyses, showed WHO regions did not show a significant difference in the publication year of study, gender of participants (male-to- pooled prevalence of NSIs in physicians (Supplementary female ratio) and WHO regions variable not significantly Figure 3). contributed to heterogeneity of NSIs prevalence of HCWs in the world (P > 0.05); but, socio-economic development Nursing students (SDI) showed a significant heterogeneity (P = 0.010), that NSIs were reported in 1154 of 3197 nursing students, explained 6.7% of between-study variation. Although, the prevalence from 11 studies was between 5.9% and publication year of study did not explain heterogene- 100%, and the pooled prevalence was 45.3% (95% CI: ity in the world, but was significant in America regions 11.2, 79.3; I2 = 99.9%). NSIs were reported in 1163 out of [Coef. = 3.5% (95% CI: 0.81, 6.2), Adj R-squared = 43.7%, 3755 medical students, the prevalence in 12 studies was P-Value = 0.016]. Table 1: Global Prevalence of Needle sticks injuries among health care workers based on SDI status and type of profession. All HCWs In nurses In physician In medical students* N Pooled ES, % I, 2 N Pooled ES, % I, 2 N Pooled ES, % I, 2 N Pooled ES, % I2, (95% CI) % (95% CI) % (95% CI) % (95% CI) % High SDI 26 37.6 (28.0, 99.8 12 28.1 (16.5, 99.8 6 39.6 (25.0, 97.7 7 34.2 (16.0, 99.4 47.3) 39.6) 54.2) 52.3) High middle 39 44.2 (30.6, 99.9 26 45.0 (36.4, 98.9 10 40.7 (21.0, 98.3 10 34.7 (0.0, 99.9 SDI 57.8) 53.5) 60.3) 71.0) Low middle 13 61.0 (50.0, 98.5 6 62.9 (39.2, 99.2 5 74.5 (63.9, 90.8 5 70.6 (48.6, 98.5 SDI 72.1) 86.7) 85.0) 94.7) Low SDI 9 41.6 (35.8, 96.5 6 43.1 (32.5, 95.0 1 10.5 (5.6, NA 0 – – 50.4) 53.6) 18.7) Global 87 44.5 (35.7, 99.9 50 42.9 (35.0, 99.7 22 46.4 (34.1, 98.8 22 42.7 (20.7, 99.9 53.2) 50.7) 58.8) 64.7) * Total Students; SDI: Socio-economic development; N: Number of included studies; HCW: Health care worker; ES: Effect size; CI: Confidence interval. Art. 35, page 6 of 8 Bouya et al: Global Prevalence and Device Related Device related causes of NSIs the following: the difference in methodology and the Among the included studies, 40 studies reported hypoder- number of studies included from each region in the pre- mic needle causes for the prevalence of NSIs, of which 25 sent study, different rules, different methods and the level studies reported suture needle, 18 reported IV cannula, 7 of supervision on the measurement of prevalence of nee- reported lancet, and 4 reported scalpel. dle stick injury in different WHO regions, the differences In these studies, of the 7065 NSI cases, 3223 were in national and regional policies in preventing needle attributed to hypodermic needle causes with a preva- stick injury, and fewer available details on precise preven- lence between 4.7% and 100%. Of the 5849 NSI cases, tion programs and annual national surveillance systems 1152 were related to suture needle and the correspond- in less developed regions such as the EMRO. However, in ing prevalence was between 2.0% and 57.1%. Of the 3913 developed countries, lower prevalence of NSIs could be NSI cases, 1034 were related to IV cannula and the cor- due to the existence of comprehensive hospital-level NSI responding prevalence was between 2.6% and 83.6%. Of prevention programs, the provision of training courses the 1297 NSI cases, 89 were related to lancet and the cor- and the provision of accurate information related to responding prevalence was between 2.3% and 12.9%. Of the management of NSIs, incentive systems for report- the 1112 NSIs cases, 131 were related to scalpel and the ing NSI cases in hospitals, categorizing NSIs as a prior- corresponding prevalence was between 7.0% and 18.8%. ity, establishing a preventive perspective on NSIs among Based on the results of random effect method, between HCWs, introducing practical policies including the use of five NSIs causes, pooled prevalence of hypodermic nee- new equipment to reduce NSIs, banning of recapping of dle was significantly higher than other causes [55.1% needles, and providing HCWs with support in the event of (95% CI: 41.4, 68.9; I2 = 99.7%)]. After hypodermic nee- NSIs, including: tests required, post exposure prophylaxis dle, pooled prevalence of IV cannula causes [23.0% (95% (PEP), counseling, rehabilitation and compensation for CI: 11.2, 34.8; I2 = 99.2%)] was prevalent and then suture the financial and psychological damage of the affected needle [19.6% (95% CI: 14.8, 24.4; I2 = 97.4%)] and scalpel person, and creating a safe work environment [26–28]. [16.8% (95% CI: 7.7, 26.0; I2 = 91.8%)]. Between causes, Among HCWs, NSIs were more prevalent among den- lancet cause was lower pooled prevalence of NSIs [7.0% tists. Unlike annual American studies and previous review (95% CI: 3.7, 10.2; I2 = 80.5%)]. studies, the highest prevalence of NSIs occurred among nurses [11, 29]. In the present study, the higher prevalence Discussion of NSIs among dentists could be due to the nature of den- NSI is one of the major safety challenges in the health tistry and the higher contact with sharp objects causing care system worldwide. To the best of our knowledge, this injuries. Based on previous studies, higher prevalence of is the first systematic review and meta-analysis that spe- NSIs among nurses shows the direct activity associated cifically examines the global prevalence of NSIs among with NSIs in them [30]. HCWs. A total of 87 studies performed on 50,916 people Unlike countries with a middle-to-low SDI, in coun- from 31 countries were included in the final stage of the tries with a better economic situation, the prevalence analysis. The global prevalence of NSIs among HCWs was of NSIs was lower. The NSI-related economic burden is a 44.5%. The results of this study indicate a high preva- very important factor while addressing and preventing it lence of NSIs among HCWs. No prior review studies have in developed countries. The lower prevalence of NSIs in focused on this purpose. However, a review aimed at eval- developed countries can be attributed to the allocation of uating percutaneous injuries, referred to NSIs as the most sufficient budget to create a safe environment, prevention important cause for contact injuries (35.3%), which, in programs, and appropriate prevention equipment [12, 31]. contrary to the present study, shows a higher prevalence Globally, the most common causes of NSIs among HCWs of needle stick injuries (44.5%) [20]. Such a high preva- were hypodermic needle (55.1%), IV cannula (23%), and lence can be attributed to demographic characteristics needle suture (19.6%). The higher prevalence of hypoder- (old age and educational level), history of training on nee- mic needle -induced NSIs may be due to the fact that the dle stick management, and number of shifts per month riskiest procedures are performed using syringe. IV can- [21]. Additionally, needle sticking is a stressful process, nula and suture needles cause NSIs injury less frequently. especially if a person is exposed to high-risk patients such Limitations: 1. The information was not fully reported as hepatitis C and HIV that subsequently affect the men- in many of the included studies, and the authors were tal health status of the individual. In this regard, studies contacted for obtaining information. 2. Studies were show that 42% to 60% of HCWs suffer from stress and carried out in only 31 countries of the world. 3. Most of depression due to NSIs [22, 23]. The prevalence of NSIs the studies were from countries with a middle to high in the EMRO region was 2 times higher than that of the economic level, which limits the interpretation of results, American and the Western Pacific regions. The lowest especially for low income countries. 4. All the studies prevalence was observed in the American region, which were cross-sectional, and special methodology limitations is consistent with previous studies that examined percuta- of these studies should be considered when interpreting neous injuries [20, 24, 25]. their results. 5. The data were collected in a self-reported Although the exact cause for the various prevalence manner in most studies that may have affected the NSIs rates in regions is unknown, the lower prevalence in prevalence rate. Despite the aforementioned limitations, developed regions such as Europe and the United States this study has many strengths. A systematic review and compared to other regions of the world may be due to meta-analysis approach was used in the present study. Bouya et al: Global Prevalence and Device Related Art. 35, page 7 of 8 Moreover, we have showed the global prevalence of NSIs 2019; Available from: https://www.cdc.gov/niosh/ based on income status in regions. stopsticks/sharpsinjuries.html. 4. Himmelreich H, Rabenau HF, Rindermann M, Conclusion et al. The management of needlestick injuries. In conclusion the results indicate a high global preva- Deutsches Ärzteblatt International. 2013; 110(5): 61. lence of NSIs among HCWs. The high prevalence of NSIs, DOI: https://doi.org/10.3238/arztebl.2013.0061 despite existing strategies, indicates the inadequacy of 5. Pruss-Ustun A, Rapiti E, Hutin Y. Estimation of current management strategies or the lack of adequate the global burden of disease attributable to contam- adherence of available standard precautions to prevent inated sharps injuries among health-care workers. NSIs. Revising existing programs to integrate diverse pro- American journal of industrial medicine. 2005; grams in developed countries, as well as to apply the basic 48(6): 482–90. Epub 2005/11/22. DOI: https://doi. principles of NSIs prevention in less developed countries org/10.1002/ajim.20230 that do not follow a systematic NSIs management pro- 6. King KC, Strony R. Needlestick. StatPearls. Treas- gram, as well as the provision and implementation of ure Island, FL: StatPearls Publishing StatPearls standard training programs to enhance knowledge, per- Publishing LLC; 2019. formance, and creating a positive attitude among HCWs 7. Reddy VK, Lavoie MC, Verbeek JH, Pahwa M. is vital. The results of this study can be used as a basis for Devices for preventing percutaneous exposure injuries planning by health policymakers and healthcare workers. caused by needles in healthcare personnel. Cochrane Paying attention to the following items can reduce the Database of Systematic Reviews. 2017(11). DOI: NSI rate: https://doi.org/10.1002/14651858.CD009740.pub3 8. Alhazmi RA, Parker RD, Wen S. Needlestick Inju- – Applying standard precautions. ries Among Emergency Medical Services Providers – Periodic training to the HCWs on NSIs prevention in Urban and Rural Areas. Journal of Community and correct recapping. Health. 2018; 43(3): 518–23. DOI: https://doi. – Develop a long-term NSIs reporting system for better org/10.1007/s10900-017-0446-0 management. 9. Mannocci A, De Carli G, Di Bari V, et al. How much – Creating an appropriate safety and organizational do needlestick injuries cost? A systematic review of culture among HCWs to encourage them for report the economic evaluations of needlestick and sharps of NSIs cases to the management. injuries among healthcare personnel. Infection Con- – Establish clear and uniform policies across all trol & Hospital Epidemiology. 2016; 37(6): 635–46. hospitals about management of NSIs. DOI: https://doi.org/10.1017/ice.2016.48 – Hospital infection control committees should reg- 10. Grimmond T, Good L. Exposure Survey of Trends ularly monitor the implementation of standard in Occupational Practice (EXPO-S.T.O.P.) 2015: A precautions guidelines. national survey of sharps injuries and mucocutane- – Perform periodic verbal and practical tests on staff ous blood exposures among health care workers in knowledge, attitude, and performance regarding US hospitals. American Journal of Infection Control. standard precautions of NSIs. 2017; 45(11): 1218–23. Epub 2017/07/25. DOI: https://doi.org/10.1016/j.ajic.2017.05.023 Additional File 11. Administration OSH. Facts about hospital worker The additional file for this article can be found as follows: safety. Washington, DC, USA: OSHA; 2013. 12. Cooke CE, Stephens JM. Clinical, economic, and • Supplementary file. PRISMA checklist, Keyword used humanistic burden of needlestick injuries in health- for search, Demographic characteristics of included care workers. Medical Devices (Auckland, NZ). 2017; studies, and prevalence of NSI among physicians and 10: 225. DOI: https://doi.org/10.2147/MDER.S140846 nurses. DOI: https://doi.org/10.5334/aogh.2698.s1 13. Kasatpibal N, Whitney JD, Katechanok S, et al. Prevalence and risk factors of needlestick inju- Competing Interests ries, sharps injuries, and blood and body fluid The authors have no competing interests to declare. exposures among operating room nurses in Thai- land. American Journal of Infection Control. 2016; References 44(1): 85–90. DOI: https://doi.org/10.1016/j. 1. World Health Organization (WHO). Needlestick ajic.2015.07.028 injuries. 2019; Available from: https://www.who. 14. Santos LTd, Rocha FLR, Marziale MHP. Needle- int/occupational_health/topics/needinjuries/en/. sticks with safety devices and accident prevention: 2. Whitby RM, McLaws ML. Hollow‐bore needlestick an integrative review. Revista brasileira de enfer- injuries in a tertiary teaching hospital: epidemiol- magem. 2018; 71(6): 3084–92. DOI: https://doi. ogy, education and engineering. Medical Journal of org/10.1590/0034-7167-2017-0719 Australia. 2002; 177(8): 418–22. DOI: https://doi. 15. Verbeek J, Basnet P. Incidence of sharps injuries in org/10.5694/j.1326-5377.2002.tb04881.x surgical units, a meta-analysis and meta-regression. 3. Centers for Disease Control and Prevention American Journal of Infection Control; 2018. DOI: (CDC). STOP STICKS CAMPAIGN–Sharps Injuries. https://doi.org/10.1016/j.ajic.2018.10.003 Art. 35, page 8 of 8 Bouya et al: Global Prevalence and Device Related 16. Pervaiz M, Gilbert R, Ali N. The prevalence and 23. Lee WC, Nicklasson L, Cobden D, Chen E, Conway underreporting of needlestick injuries among den- D, Pashos CL. Short-term economic impact associ- tal healthcare workers in Pakistan: A systematic ated with occupational needlestick injuries among review. International Journal of Dentistry; 2018. DOI: acute care nurses. Current Medical Research and https://doi.org/10.1155/2018/9609038 Opinion. 2005; 21(12): 1915–22. Epub 2005/12/22. 17. Fereidouni Z, Kameli Morandini M, Dehghan DOI: https://doi.org/10.1185/030079905X65286 A, Jamshidi N, Najafi Kalyani M. The Prevalence 24. Auta A, Adewuyi EO, Tor-Anyiin A, et al. Health- of Needlestick Injuries and Exposure to Blood and care workers’ occupational exposures to body Body Fluids Among Iranian Healthcare Workers: A fluids in 21 countries in Africa: Systematic review Systematic Review. International Journal of Medi- and meta-analysis. Bulletin of the World Health cal Reviews. 2018; 5(1): 35–40. DOI: https://doi. Organization. 2017; 95(12): 831. DOI: https://doi. org/10.29252/IJMR-050106 org/10.2471/BLT.17.195735 18. Moher D, Liberati A, Tetzlaff J, Altman DG, 25. Prüss-Üstün A, Rapiti E, Hutin Y. Global burden Group P. Preferred reporting items for systematic of disease from sharps injuries to health-care work- reviews and meta-analyses: the PRISMA statement. ers. Environmental Burden of Disease Series, No. 3. PLoS medicine. 2009; 6(7): e1000097. DOI: https:// Geneva: World Health Organization Protection of doi.org/10.1371/journal.pmed.1000097 the Human Environment; 2003. 19. Hoy D, Brooks P, Woolf A, et al. Assessing risk of 26. BD. Safety-europe. 2019; Available from: https:// bias in prevalence studies: Modification of an exist- www.bd.com/europe/safety/en/regulation/. ing tool and evidence of interrater agreement. Jour- 27. Network Eb. Prevention of Sharps Injuries in the nal of Clinical Epidemiology. 2012; 65(9): 934–9. Hospital and Healthcare Sector 2017. DOI: https://doi.org/10.1016/j.jclinepi.2011.11.014 28. Centers for Disease Control and Prevention 20. Auta A, Adewuyi EO, Tor-Anyiin A, et al. Global (CDC). How to Prevent Needlestick and Sharps Inju- prevalence of percutaneous injuries among ries? 2012. healthcare workers: A systematic review and meta- 29. Elseviers MM, Arias-Guillén M, Gorke A, Arens analysis. International journal of epidemiology. 2018; HJ. Sharps injuries amongst healthcare workers: 47(6): 1972–80. Epub 2018/10/03. DOI: https:// review of incidence, transmissions and costs. Jour- doi.org/10.1093/ije/dyy208 nal of Renal Care. 2014; 40(3): 150–6. DOI: https:// 21. Motaarefi H, Mahmoudi H, Mohammadi E, doi.org/10.1111/jorc.12050 Hasanpour-Dehkordi A. Factors Associated with 30. Gabriella De Carli M, Puro V, Ippolito G. Risk of Needlestick Injuries in Health Care Occupations: hepatitis C virus transmission following per-cutane- A Systematic Review. J Clin Diagn Res. 2016; 10(8): ous exposure in healthcare workers. Infection. 2003; IE01–IE4. Epub 2016/08/01. DOI: https://doi. 31(5). org/10.7860/JCDR/2016/17973.8221 31. Lee JM, Botteman MF, Xanthakos N, Nicklasson 22. Lee JM, Botteman MF, Nicklasson L, Cobden D, L. Needlestick injuries in the United States. Epi- Pashos CL. Needlestick injury in acute care nurses demiologic, economic, and quality of life issues. caring for patients with diabetes mellitus: A retro- AAOHN journal: Official Journal of the American spective study. Current Medical Research and Opin- Association of Occupational Health Nurses. 2005; ion. 2005; 21(5): 741–7. Epub 2005/06/23. DOI: 53(3): 117–33. Epub 2005/03/26. DOI: https://doi. https://doi.org/10.1185/030079905X46205 org/10.1177/216507990505300311 How to cite this article: Bouya S, Balouchi A, Rafiemanesh H, Amirshahi M, Dastres M, Moghadam MP, Behnamfar N, Shyeback M, Badakhsh M, Allahyari J, Al Mawali A, Ebadi A, Dezhkam A, Daley KA. Global Prevalence and Device Related Causes of Needle Stick Injuries among Health Care Workers: A Systematic Review and Meta-Analysis. Annals of Global Health. 2020; 86(1): 35, 1–8. DOI: https://doi.org/10.5334/aogh.2698 Published: 06 April 2020 Copyright: © 2020 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See http://creativecommons.org/licenses/by/4.0/. Annals of Global Health is a peer-reviewed open access journal published by Ubiquity Press. OPEN ACCESS Riigihangete vaidlustuskomisjon Teie 30.05.2025 [email protected] Meie 04.06.2025 nr 2-6/147-2 Vastus ISIS Medical OÜ vaidlustusele riigihankes „Katsutite ja verevõtuvahendite ostmine“, viitenumber 294368 Hankija: AS Lääne-Tallinna Keskhaigla registrikood: 10822269 aadress: Paldiski mnt 68, 10617 Tallinn Hankija esindaja: jurist Kaisa Suvi telefon: 6507 399 e-post: [email protected] Vaidlustaja: ISIS Medical OÜ registrikood: 10958649 aadress Urda tee 2/1, Jälgimäe, Saku vald, Harjumaa 76404 Vaidlustaja esindaja: advokaat Toomas Pugri e-post: [email protected] 1. SENINE MENETLUS ISIS Medical OÜ (vaidlustaja) esitas 30.05.2025 vaidlustuse (vaidlustus) riigihankes „Katsutite ja verevõtuvahendite ostmine“ viitenumbriga 294368 (riigihange). Vaidlustaja taotles riigihangete vaidlustuskomisjoni (VAKO) kohustama AS-i Lääne-Tallinna Keskhaigla (hankija) viima riigihanke alusdokumendid osas 1 vaidlustaja soovidega kooskõlla. VAKO edastas vaidlustuse hankijale 30.05.2025 ning palus hankijal esitada kirjalik seletus vaidlustuse kohta ja asja lahendamiseks vajalikud dokumendid hiljemalt 04.06.2025. Käesolevaga esitab hankija enda vastuse vaidlustuse osas. AS Lääne-Tallinna Keskhaigla, Paldiski mnt 68, 10617 Tallinn, Eesti Vabariik Telefon: 650 7393, Faks 650 7265, e-post [email protected] Registrikood: 10822269, Arvelduskonto: EE081010220022881019 SEB Pank 2. RIIGIHANKE ALUSDOKUMENTIDE MUUTMINE Hankija annab teada, et on 04.06.2025 muutunud riigihanke alusdokumente ning pikendanud pakkumuste esitamise tähtaega kuni 03.07.2025. Muudetud tehniline kirjeldus (Lisa 1) ja hindamiskriteeriumid (Lisa 2) on lisatud riigihangete registrisse ning avaldatakse riigihangete registris vastavalt hanketeadete avaldamise korrale. 3. HINDAMISKRITEERIUMITE ÕIGUSPÄRASUS 3.1 Verevõtuvahendite turg Vaidlustaja väidab vaidlustuses, et Eestis on verevõtuvahendite turul sisuliselt kaks rahvusvaheliselt tunnustatud brändi/toodet, millest ühte esindab vaidlustaja ja teist AS Surgitech ning riigihanke osa 1 hindamiskriteeriumi „Täiendav funktsionaalsus“ punktidele 1 ja 2 vastavat toodet suudab pakkuda vaid üks pakkuja – Becton, Dickinson and Company. Vaidlustaja väidab, et hankija on rikkunud konkurentsi efektiivse ärakasutamise ja rahaliste vahendite säästliku ja otstarbeka kasutamise põhimõtet. Hankija vaidlustaja väidetega ei nõustu. Hankija selgitab, et lisaks vaidlustajale ning vaidlustaja poolt viidatud AS-le Surgitech on Eesti turul ka teisi pakkujaid, kes verevõtuvahendeid pakuvad1. Verevõtuvahendite turul on mitmeid brände, kelle tooted vastavad vaidluse all oleva hindamiskriteeriumi „Täiendav funktsionaalsus“ punktidele 1 ja 2 – näiteks Disera2, Metze Care3, KDL4, Boen Healthcare5, Sol-Millennium Medical6 jne. Seega ei ole tõene vaidlustaja väide, et hindamiskriteeriumi „Täiendav funktsionaalsus“ punktidele 1 ja 2 vastavat toodet suudab pakkuda vaid üks pakkuja. 3.2 Hindamiskriteeriumite põhjendatus Vaidlustaja väitel muudab hindamiskriteeriumi „Täiendav funktsionaalsus“ punktide 1 ja 2 jaotamine toote maksumuse kriteeriumi olemuselt sisutühjaks ning hankijal ei ole võimalik oma rahalisi vahendeid säästlikult ja otstarbekalt kasutada. Vaidlustaja väidab, et hindamiskriteeriumi „Täiendav funktsionaalsus“ punktid 3-5 on põhjendamatult subjektiivselt hinnatavad ega ole tagatud hindamisprotsessi läbipaistvus ja kontrollitavus. Vaidlustaja väitel ei ole tingimuste täitmist võimalik mõõta objektiivsete tehniliste parameetrite või dokumentaalselt tõendatavate näitajate alusel, vaid hinnang sõltub üksnes hankija subjektiivsest tajust. Hankija vaidlustaja väidetega ei nõustu. Riigihangete seaduse (RHS) § 85 lg 3 ja 8 kohaselt võtab hankija majanduslikult soodsaima pakkumuse väljaselgitamisel arvesse eelkõige parimat hinna ja kvaliteedi suhet (nt tehniline 1 Nt hankija eelmisele riigihankele viitenumbriga 263595 esitas pakkumuse AS Mediq. SA Põhja-Eesti Regionaalhaigla 2024.a läbiviidud riigihanke osale 2 (proovivõtutarvikud) viitenumbriga 268561 esitas pakkumuse Balmung Medical Handel GmbH 2 Lisa 3 Disera kataloog, lk 24 „Vacusera Blood Collection Needles are also available with integrated safety cap and window (Vision).“ 3 Lisa 4 väljavõte Metze Care kataloogist, lk 32-33 4 Lisa 5 väljavõte KDL kataloogist, lk 3-4 5 https://www.boenmedical.com/?products=safety-multi-sample-needle-visible 6 Lisa 6 väljavõte Sol-Millennium Medical kataloogist, lk 7 väärtus, funktsionaalsed ja innovaatilised omadused). Hindamise kriteeriumite valimine on hankija kaalutlusotsus.7 Hankijal on õigus ise otsustada, mil viisil ja mille alusel ta hindamiskriteeriumi formuleerib. Hankijal on hindamiskriteeriumite ja nende osakaalu määratlemisel ulatuslik kaalutlusruum ning majanduslikult soodsaima pakkumuse väljaselgitamiseks kasutatavad kriteeriumid ei pea tingimata olema laadilt kvantitatiivsed või puudutama ainuüksi hindu8. Hankija võib lisaks hinnale ja kulule arvesse võtta ka mittemajanduslikke kvaliteedikriteeriume, isegi kui selliste kriteeriumite seadmine võib kaasa tuua pakkumuste maksumuste kallinemise.9 Võrdse kohtlemise põhimõte ei keela hindamise kriteeriumi kasutada üksnes seetõttu, et vaid üksikutel ettevõtjatel on võimalik selle kriteeriumi eest punkte saada.10 3.2.1 Hindamiskriteeriumi „Täiendav funktsionaalsus“ punktid 1-2 Hankija on otsustanud riigihanke osas 1 hindamiskriteeriumi „Täiendav funktsionaalsus“ punktid 1-2 lisada eesmärgiga tagada patsiendi ja tervishoiutöötaja maksimaalne ohutus ning verevõtuprotseduuri kõrgeim võimalik kvaliteet. Meditsiiniline praktika ja kliiniline kogemus näitavad, et erinevused integreerimise viisis (nt kas mehhanism on nõela või nõelahoidja küljes, kas see on pöörlev või eelseatud) mõjutavad otseselt tööohutust, patsiendi turvalisust ja töövoo sujuvust. Nõela külge püsivalt integreeritud ohutusmehhanism, mis ei liigu ega keerle ümber telje, on vahetult pärast nõela eemaldamist valmis aktiveerimiseks ühe lihtsa liigutusega. Selline lahendus välistab vajaduse kaitsemehhanismi käsitsi kohandada, suunata või keerata, mis omakorda vähendab kasutajavigade ja nõelatorkevigastuste riski. Maailma Terviseorganisatsiooni hinnangul moodustavad nõelatorkevigastused vastavalt 39%, 37% ja 4,4% C-hepatiidi, B-hepatiidi ja HIV-nakkuse juhtudest11. Nõelatorkevigastused on üks levinumaid tööõnnetusi tervishoiuasutustes12. Kui ohutusmehhanism on liikuv või pööratav kasvab risk, et mehhanism jääb valesse asendisse, kasutaja unustab selle aktiveerida või aktiveerib valesti või nõel jääb ajutiselt avatuks ja potentsiaalselt ohtlikuks. Eriti kiiretes töökeskkondades – nagu EMO, intensiivravi ja verevõtukabinetid, kus lühikese aja jooksul võetakse kuni 60-l patsiendil verd – ei pruugi olla aega kontrollida, kas kaitsemehhanism on täpselt õiges asendis. Fikseeritud, mitte-liikuv mehhanism aitab säilitada nõela stabiilsust nii sisestamisel kui eemaldamisel, vähendades liikumisest põhjustatud traumasid, hemolüüsi või vere lekkimist. See on kriitilise tähtsusega tundlikel patsientidel – näiteks eakatel, lastel või nõrkade veenidega patsientidel. Fikseeritud ohutusmehhanismi korral on nõelatorkevigastuste oht madal, kuna mehhanism lukustub kohe ja ei vaja täiendavat käsitsemist. Liikuva või pööratava ohutusmehhanismi korral on nõelatorkevigastuste oht kõrgem, kuna nõel jääb avatuks, kuni kasutaja aktiveerib süsteemi käsitsi. Hankija seatud hindamise kriteeriumid tõstavad tervishoiuteenuse ohutust, kvaliteeti ja 7 Euroopa Kohtu otsused C-31/87, p 19 ja C-324/93, p 42 8 Tallinna Ringkonnakohtu 11.09.2017 otsus 3-17-1172 p 13; Tallinna Ringkonnakohtu 05.04.2018 otsus 3-17-2469, p-d 14 9 E. Fels § 85 kommentaarid 12, 13 lk 476 M. Parind, M.A. Simovart (koost). Riigihangete seadus. Kommenteeritud väljaanne. Juura 2019. 10 Euroopa Kohtu otsus C-513/99, p 86 11 https://www.who.int/tools/occupational-hazards-in-health-sector/occupational-infections 12 Lisa 7 Bouya, S. jt. Global Prevalence and Device Related Causes of Needle Stick Injuries among Health Care Workers: A Systematic Review and Meta-Analysis. s. Annals of Global Health. 2020; 86(1): 35, 1–8. tööprotsessi efektiivsust, ennetavad vigasid ning kaitsevad patsienti ja personali nakkuste ja õnnetuste eest. Hankija on kasutanud vaidlustaja poolt pakutud tooteid, kuid hankija töötajad ei ole tootega rahul, kuna pööratav ohutusmehhanism varjab vaatevälja, eeldab nõela ava suuna märgistuse otsimist ja lisaliigutusi mehhanismi keeramisega. Ebamugavate ohutusnõelte kasutama sundimise puhul tekkis osades töötajates rahulolematus ja kasutati seetõttu hoopis tavanõelu. Hankija on koostanud hindamiskriteeriumid verevõtu töötajatelt saadud põhjaliku tagasiside, kaebuste, nõudmiste ja ebamugavate toodete kasutamise vältimispraktika põhjal. Oluline on lähtuda verevõtutöötaja vajadustest, kes peab eksimatult ja kiiresti suure hulga patsiente teenindama väikses ajaühikus, vähendades stressi ja tagades ka töötaja rahulolu. 3.2.2 Hindamiskriteeriumi „Täiendav funktsionaalsus“ punktid 3-5 Vaidlust ei ole selles, et subjektiivsed hindamiskriteeriumid ei ole a priori õigusvastased, seda tunnistab vaidlustaja ka ise vaidlustuses. Kvaliteedikriteeriumid võivad sisaldada subjektiivseid elemente, mis on pakkumuse majandusliku sooduse üle otsustamisel hankija jaoks tähtsad – esteetika, mugavus jne. Kontrollitav ja objektiivne saab olla ka subjektiivsete kriteeriumide alusel toimuv hindamine13. Hankija hinnangul on punktides 3-5 libliknõela kohta piisava täpsusega selgitatud, et hindamine oleks läbipaistev ja ei tekiks subjektiivsust. Punkt 3 osas saab lisapunkte pakkumus, kus steriilse üksikpakendi avamise järgselt püsib libliknõel kindlalt pakendis. Hankija jaoks on oluline libliknõela avatud pakendiga lauale asetada, et peale ettevalmistustegevust seda ühe käega kasutamiseks haarata. Sealjuures pakendi avamisel ei tohi olla toote väljalibisemise ja saastumise ohtu. Näiteks on selline oht risti keskelt rebitaval kilepakendil ja kilepakendist puudub ka võimalus steriilset toodet otse ja ühe käega kasutamiseks haarata, ilma et seda ei peaks vahepeal lauale asetama. Punkt 4 osas saab lisapunkte pakkumus, kui libiknõela lukustatav turvakaitse on ühe käega aktiveeritav ilma abivahendeid kasutamata. Turul on mitu tootjat, kelle libliknõela kasutamise videojuhendites on toode ühe ja sama käega nii kasutatav kui ka ohutusmehhanism aktiveeritav. Hankija lähtub tootja videojuhistest hindamisel ja subjektiivsus puudub. Punkt 5 osas saab lisapunkte pakkumus, kui libliknõela kasutamisel ei teki häireid. Häirete kirjeldused on Hankija poolt täpse detailsusega välja toodud, et välistada subjektiivne hindamine. a) „Stabiilsus ja konstruktsioon – Nõel ja selle komponendid on hästi kinnitatud, ei logise ega liigu kasutamise ajal“ ei ole subjektiivne. Kui kasutamisel nõel ja selle komponendid logisevad või liiguvad, siis on häire. b) „Vooliku paindlikkus – voolik on piisavalt elastne (mitte jäik), et võimaldada lihtsat käsitsemist, ei paindu ega murdu blokeerimaks verevoolu.“ ei ole subjektiivne. Kui vool on blokeeritud, siis on häire. 13 E. Fels § 85 kommentaar 25 lk 475 M. Parind, M.A. Simovart (koost). Riigihangete seadus. Kommenteeritud väljaanne. Juura 2019 c) „Tiivad on ergonoomilised, pole liiga pehmed ega jäigad – lihtne ja kindel haare, püsivad paigas- ei vaju ära ega nihku.“ ei ole subjektiivne. Kui tiivad laperdavad ja toode seetõttu pole kindlas asendis, siis on häire. d) „Tiibade pind on libisemisvastane, kinnastega töötamisel ja käes hoidmisel mugav, ei esine häireid ega libise. Mugav käes hoida ka kinnastega töötades“ ei ole subjektiivne. Kui kindaga saab sujuvalt kasutada, pole ka häiret. e) „Turvakaitse aktiveerimisel ei esine takistusi, lukustub kindlalt, ega vaja liigse jõudu kasutamist“ ei ole subjektiivne. Nõude täitmiseks peab turvasüsteem aktiveeruma ühe sujuva liigutusega ega takerdu. Pärast aktiveerimist peab püsima nõel lukustatult fikseeritud asendis, ei võimalda korduvat kasutamist ning ei jää väljapoole nähtavale ega tunda katsudes. Kui kaitsemehhanism ei lukustu, katkeb tööprotsess või on nõel pärast lukustumist taas avatav, loetakse see häireks. f) „Ühildub nõelahoidajaga- verevool on sujuv, ei blokeeru ega leki üheski süsteemi osas.“ Ei ole subjektiivne - leket ja blokke ei tohi esineda. Hankija on 04.06.2025 muutunud riigihanke alusdokumente, sh hindamiskriteeriumi „Täiendav funktsionaalsus“ osakaalu ning selle tõttu ka täiendava funktsionaalsuse eest jagatavaid punkte (muudetud hindamiskriteeriumid). Hankija on nii varasemalt kehtinud kui muudetud hindamiskriteeriumites väga selgelt välja toonud kuidas pakkumusele punkte jagatakse. Kui häireid ei esine, saab pakkumus 6 punkti. Kui esineb 1-2 häiret, saab pakkumus 3 punkti ja kui esineb rohkem kui 2 häiret, saab pakkumus 0 punkti selle hindamiskriteeriumi eest. Hindamise kriteerium on läbipaistev, kui kriteeriumi kohaldamiseks ja hindepunktide andmiseks on riigihanke alusdokumentides kehtestatud loogiline ja üheselt mõistetav meetod. Hankija hinnangul on antud nõue täidetud. Samuti on hankija hinnangul kriteeriumite täitmist võimalik kontrollida. Riigihangete seadus ei ütle kui täpseks peab hankija minema pakkumuste hindamise kohta informatsiooni andmisel – nõutav on üksnes hindamise kriteeriumite ja igale hindamise kriteeriumile vastava suhtelise osakaalu avaldamine14. Samas, vältimaks mitmetimõistmisi, on hankija muudetud hindamiskriteeriumites veelgi spetsiifilisemalt täpsustanud mida peetakse häire all silmas (ülatoodud punktide a) kuni f) selgitused). 3.2.3 Hindamiskriteeriumi „Täiendav funktsionaalsus“ osakaal Hankija on 04.06.2025 muutunud riigihanke alusdokumente, sh hindamiskriteeriumite osakaalu. Hankija otsustada on milline osakaal hinnale määrata. Osakaalude määramisega saab hankija diferentseerida hindamise kriteeriumide tähtsust ja vältida vähem oluliste kriteeriumide võrdsustamist kriteeriumidega, millel on majanduslikult soodaima pakkumuse väljaselgitamisel hankijale suurem tähtsus. RHS § 85 lg 9 ega ükski muu RHS säte ei reguleeri, millise osakaalu peaks hankija pakkumuste hindamise kriteeriumidele seadma.15 14 E. Fels § 85 kommentaar 10 lk 475 M. Parind, M.A. Simovart (koost). Riigihangete seadus. Kommenteeritud väljaanne. Juura 2019 15 E. Fels § 85 kommentaarid 35, 82 ja 84 lk 482, 496 M. Parind, M.A. Simovart (koost). Riigihangete seadus. Kommenteeritud väljaanne. Juura 2019 Hankija on otsustanud muudetud hindamiskriteeriumite seadmisel, et patsientide ja töötajate ohutus, turvalised töötingimused ning osutatava tervishoiuteenuse kvaliteet on niivõrd olulise kaaluga, et põhjendatud on täiendava funktsionaalsuse eest anda 31 punkti. Samas võtab hankija siiski arvesse ka hinda, kuna väikseima maksumusega pakkumus saab maksimaalselt 69 punkti. Hankija seatud hindamise kriteeriumid ei piira konkurentsi - iga hindamise kriteeriumi täitmine ei ole pakkujatele kohustuslik, erinevalt tehniliselt kirjeldusest või kvalifitseerimise tingimusest. Samuti on võimalik pakkumus esitada vaidlustajal. Kuigi vaidlustaja ei ole vaidlustanud osa 2 alusdokumente, lisab hankija märkuse korras, et osas 2 nimetatud libliknõela kasutatakse hankija naistekliinikus imikute verevõtul, kus kõige olulisem vastavustingimus on optimaalne vooliku pikkus – voolik ei tohi olla liiga lühike ega liiga pikk (tehnilise kirjelduse kohaselt on sobiv pikkus 160-180mm). Hankija on osa 2 hindamiskriteeriumi sätestamisel lähtunud sellest, et toote kvaliteedinõuded on võimalik ammendavalt sätestada tehnilises kirjelduses. 4. MENETLUSLIKUD KÜSIMUSED Hankija leiab, et vaidlustuse läbivaatamine istungil ei ole vajalik. Juhul, kui VAKO peaks otsustama vastupidist, soovib hankija istungil osaleda. Eeltoodud asjaolusid arvesse võttes palub hankija: 1. jätta vaidlustaja vaidlustus rahuldamata; 2. lahendada asi kirjalikus menetluses; 3. jätta menetluskulud täies ulatuses vaidlustaja kanda. Lugupidamisega (allkirjastatud digitaalselt) Kaisa Suvi Volitatud esindaja Lisatud: Lisa 1 Tehniline kirjeldus Lisa 2 Hindamiskriteeriumid Lisa 3 Disera kataloog Lisa 4 väljavõte Metze Care kataloogist Lisa 5 väljavõte KDL kataloogist Lisa 6 väljavõte Sol-Millennium Medical kataloogist Lisa 7 Bouya, S. jt. Global Prevalence and Device Related Causes of Needle Stick Injuries among Health Care Workers: A Systematic Review and Meta-Analysis. s. Annals of Global Health. 2020; 86(1): 35, 1–8. Lisa 8 Volikiri Riigihangete vaidlustuskomisjon Tartu mnt 85 10115 Tallinn Meie 02.06.2025 nr 2-10/15 [email protected] VOLIKIRI 1. Käesolevaga volitab AS Lääne-Tallinna Keskhaigla (edaspidi LTKH) õigus- ja hankeosakonna juristi Kaisa Suvi (isikukood 48705290369) esindama LTKH-t riigihangete vaidlustuskomisjonis vaidlustusmenetluses riigihankele „Katsutite ja verevõtuvahendite ostmine“, viitenumber 294368. Esindajal on õigus teha LTKH nimel kõiki menetlustoiminguid. 2. Volikiri on antud edasivolitamise õiguseta ning on tähtajatu. (allkirjastatud digitaalselt) Arkadi Popov juhatuse esimees [email protected] AS Lääne-Tallinna Keskhaigla, Paldiski mnt 68, 10617 Tallinn, Eesti Vabariik Telefon: 650 7393, Faks 650 7265, e-post [email protected] Registrikood: 10822269, Arvelduskonto: EE081010220022881019 SEB Pank SOL-CARE™ Safety Multi-Sample Needle Blood Collection Devices SOL-CARE™ Safety Multi-Sample Blood Collection Needle* is a safety-engineered tool for multi-sample venous blood collection. The device is designed with a safety mechanism covering the needle after use. In the activated position, the needle cover guards against accidental needlestick during normal handling and disposal. It is also offered with a pre-attached holder. 0123 SOL-CARE™ Safety Multi-Sample Needle Needle outer diameter Needle length Reference number Gauge Millimeters Inches Millimeters SMSN22125 22G 0.7 mm 1 1/4” 32 mm SMSN2215 22G 0.7 mm 1 1/2” 38 mm SMSN21125 21G 0.8 mm 1 1/4” 32 mm SMSN2115 21G 0.8 mm 1 1/2” 38 mm SMSN20125 20G 0.9 mm 1 1/4” 32 mm SMSN2015 20G 0.9 mm 1 1/2” 38 mm Sales Unit: 48 pcs/Box; 480 pcs/Case 0123 Millimeters SOL-CARE™ Safety Multi-Sample Needle with Pre-attached Holder Needle outer diameter Needle length Reference number Gauge Millimeters Inches SMSNH22125 22G 0.7 mm 1 1/4” 32 mm SMSNH2215 22G 0.7 mm 1 1/2” 38 mm SMSNH21125 21G 0.8 mm 1 1/4” 32 mm SMSNH2115 21G 0.8 mm 1 1/2” 38 mm SMSNH20125 20G 0.9 mm 1 1/4” 32 mm SMSNH2015 20G 0.9 mm 1 1/2” 38 mm Sales Unit: 50 pcs/Box; 400 pcs/Case *Please verify the availability of the products in your region 07

Allikas: Rahandusministeerium dokumendiregister →